0001558370-21-003925.txt : 20210401 0001558370-21-003925.hdr.sgml : 20210401 20210401173026 ACCESSION NUMBER: 0001558370-21-003925 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 118 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210401 DATE AS OF CHANGE: 20210401 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GENERAL CANNABIS CORP CENTRAL INDEX KEY: 0001477009 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-DETECTIVE, GUARD & ARMORED CAR SERVICES [7381] IRS NUMBER: 208096131 STATE OF INCORPORATION: CO FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-54457 FILM NUMBER: 21799487 BUSINESS ADDRESS: STREET 1: 6565 EAST EVANS AVENUE CITY: DENVER STATE: CO ZIP: 80224 BUSINESS PHONE: 303-759-1300 MAIL ADDRESS: STREET 1: 6565 EAST EVANS AVENUE CITY: DENVER STATE: CO ZIP: 80224 FORMER COMPANY: FORMER CONFORMED NAME: Advanced Cannabis Solutions, Inc. DATE OF NAME CHANGE: 20131023 FORMER COMPANY: FORMER CONFORMED NAME: Promap Corp DATE OF NAME CHANGE: 20091117 10-K 1 cann-20201231x10k.htm 10-K
0001477009--12-312020FYfalsetrue00CONONE3949748060813673P1Y246250187742354858140001477009cann:Warrants10percentMemberus-gaap:MeasurementInputSharePriceMember2020-12-310001477009cann:Warrants10percentMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2020-12-310001477009cann:Warrants10percentMemberus-gaap:MeasurementInputPriceVolatilityMember2020-12-310001477009cann:Warrants10percentMemberus-gaap:MeasurementInputExpectedTermMember2020-12-310001477009cann:Warrants10percentMemberus-gaap:MeasurementInputExercisePriceMember2020-12-310001477009cann:TwentyThousandAndNineteenWarrantsMemberus-gaap:MeasurementInputSharePriceMember2020-12-310001477009cann:TwentyThousandAndNineteenWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2020-12-310001477009cann:TwentyThousandAndNineteenWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2020-12-310001477009cann:TwentyThousandAndNineteenWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2020-12-310001477009cann:TwentyThousandAndNineteenWarrantsMemberus-gaap:MeasurementInputExercisePriceMember2020-12-310001477009cann:TwentyThousandAndNineteenWarrantsMembercann:MeasurementInputNumberOfSharesUnderlyingWarrantsOutstandingMember2020-12-310001477009srt:MinimumMembercann:Warrants15PercentMemberus-gaap:MeasurementInputSharePriceMember2020-03-310001477009srt:MinimumMembercann:Warrants15PercentMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2020-03-310001477009srt:MinimumMembercann:Warrants15PercentMemberus-gaap:MeasurementInputPriceVolatilityMember2020-03-310001477009srt:MinimumMembercann:Warrants15PercentMemberus-gaap:MeasurementInputExpectedTermMember2020-03-310001477009srt:MaximumMembercann:Warrants15PercentMemberus-gaap:MeasurementInputSharePriceMember2020-03-310001477009srt:MaximumMembercann:Warrants15PercentMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2020-03-310001477009srt:MaximumMembercann:Warrants15PercentMemberus-gaap:MeasurementInputPriceVolatilityMember2020-03-310001477009srt:MaximumMembercann:Warrants15PercentMemberus-gaap:MeasurementInputExpectedTermMember2020-03-310001477009cann:Warrants15PercentMemberus-gaap:MeasurementInputExercisePriceMember2020-03-310001477009cann:TwentyThousandAndNineteenWarrantsMemberus-gaap:MeasurementInputSharePriceMember2019-12-310001477009cann:TwentyThousandAndNineteenWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2019-12-310001477009cann:TwentyThousandAndNineteenWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2019-12-310001477009cann:TwentyThousandAndNineteenWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2019-12-310001477009cann:TwentyThousandAndNineteenWarrantsMemberus-gaap:MeasurementInputExercisePriceMember2019-12-310001477009cann:TwentyThousandAndNineteenWarrantsMembercann:MeasurementInputNumberOfSharesUnderlyingWarrantsOutstandingMember2019-12-310001477009srt:MinimumMembercann:Warrants12PercentMemberus-gaap:MeasurementInputSharePriceMember2019-09-300001477009srt:MinimumMembercann:Warrants12PercentMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2019-09-300001477009srt:MaximumMembercann:Warrants12PercentMemberus-gaap:MeasurementInputSharePriceMember2019-09-300001477009srt:MaximumMembercann:Warrants12PercentMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2019-09-300001477009cann:Warrants12PercentMemberus-gaap:MeasurementInputPriceVolatilityMember2019-09-300001477009cann:Warrants12PercentMemberus-gaap:MeasurementInputExpectedTermMember2019-09-300001477009cann:Warrants12PercentMemberus-gaap:MeasurementInputExercisePriceMember2019-09-300001477009cann:TwentyThousandAndNineteenWarrantsMemberus-gaap:MeasurementInputSharePriceMember2019-05-310001477009cann:TwentyThousandAndNineteenWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2019-05-310001477009cann:TwentyThousandAndNineteenWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2019-05-310001477009cann:TwentyThousandAndNineteenWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2019-05-310001477009cann:TwentyThousandAndNineteenWarrantsMemberus-gaap:MeasurementInputExercisePriceMember2019-05-310001477009cann:TwentyThousandAndNineteenWarrantsMembercann:MeasurementInputNumberOfSharesUnderlyingWarrantsOutstandingMember2019-05-310001477009cann:Warrants8.5PercentMemberus-gaap:MeasurementInputSharePriceMember2018-04-300001477009cann:Warrants8.5PercentMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2018-04-300001477009cann:Warrants8.5PercentMemberus-gaap:MeasurementInputPriceVolatilityMember2018-04-300001477009cann:Warrants8.5PercentMemberus-gaap:MeasurementInputExpectedTermMember2018-04-300001477009cann:Warrants8.5PercentMemberus-gaap:MeasurementInputExercisePriceMember2018-04-300001477009cann:Warrants8.5PercentMembercann:MeasurementInputNumberOfIterationsMember2018-04-300001477009cann:TwentyThousandAndNineteenWarrantsMember2020-05-012020-05-310001477009cann:TwentyThousandAndNineteenWarrantsMember2019-10-012019-12-310001477009us-gaap:EmployeeStockOptionMember2020-04-012020-06-300001477009us-gaap:RetainedEarningsMember2020-12-310001477009us-gaap:AdditionalPaidInCapitalMember2020-12-310001477009us-gaap:RetainedEarningsMember2019-12-310001477009us-gaap:AdditionalPaidInCapitalMember2019-12-310001477009us-gaap:RetainedEarningsMember2018-12-310001477009us-gaap:AdditionalPaidInCapitalMember2018-12-3100014770092020-05-290001477009us-gaap:CommonStockMember2020-12-310001477009us-gaap:CommonStockMember2019-12-310001477009us-gaap:CommonStockMember2018-12-310001477009cann:PreTriggerMembercann:Warrants15PercentMember2019-10-182019-10-180001477009cann:PostTriggerMembercann:Warrants15PercentMember2019-10-182019-10-180001477009cann:WarrantsWithDebtMember2019-12-310001477009cann:ConsultingAwardsMember2019-12-310001477009cann:WarrantsWithDebtMember2018-12-310001477009cann:OmnibusIncentivePlan2020Member2020-01-012020-12-310001477009cann:WarrantsWithDebtMember2019-01-012019-12-310001477009cann:EmployeeAwardsMember2020-12-310001477009cann:EmployeeAwardsMember2019-12-310001477009cann:IncentivePlanMember2020-12-310001477009cann:OmnibusIncentivePlan2020Member2020-12-3100014770092018-04-300001477009cann:IncentivePlanMember2014-10-290001477009srt:MinimumMembercann:EmployeeAwardsMember2020-01-012020-12-310001477009srt:MaximumMembercann:EmployeeAwardsMember2020-01-012020-12-310001477009srt:MinimumMembercann:EmployeeAwardsMember2019-01-012019-12-310001477009srt:MaximumMembercann:EmployeeAwardsMember2019-01-012019-12-310001477009cann:PreTriggerMembercann:Warrants15PercentMember2019-12-112019-12-110001477009cann:PreTriggerMembercann:EightPointFivePercentWarrantsMember2019-12-112019-12-110001477009cann:PostTriggerMembercann:Warrants15PercentMember2019-12-112019-12-110001477009cann:PostTriggerMembercann:EightPointFivePercentWarrantsMember2019-12-112019-12-110001477009cann:PreTriggerMembercann:Warrants15PercentMember2019-11-012019-11-010001477009cann:PreTriggerMembercann:EightPointFivePercentWarrantsMember2019-11-012019-11-010001477009cann:PostTriggerMembercann:Warrants15PercentMember2019-11-012019-11-010001477009cann:PostTriggerMembercann:EightPointFivePercentWarrantsMember2019-11-012019-11-010001477009srt:MinimumMembercann:PreTriggerMembercann:Warrants15PercentMember2019-10-182019-10-180001477009srt:MinimumMembercann:PostTriggerMembercann:Warrants15PercentMember2019-10-182019-10-180001477009srt:MaximumMembercann:PreTriggerMembercann:Warrants15PercentMember2019-10-182019-10-180001477009srt:MaximumMembercann:PostTriggerMembercann:Warrants15PercentMember2019-10-182019-10-180001477009cann:PreTriggerMembercann:EightPointFivePercentWarrantsMember2019-10-182019-10-180001477009cann:PostTriggerMembercann:EightPointFivePercentWarrantsMember2019-10-182019-10-180001477009srt:MinimumMembercann:ConsultingAwardsMember2019-01-012019-12-310001477009srt:MaximumMembercann:ConsultingAwardsMember2019-01-012019-12-310001477009cann:EmployeeAwardsMember2019-01-012019-12-310001477009cann:PreTriggerMembercann:Warrants15PercentMember2019-12-110001477009cann:PreTriggerMembercann:EightPointFivePercentWarrantsMember2019-12-110001477009cann:PostTriggerMembercann:Warrants15PercentMember2019-12-110001477009cann:PostTriggerMembercann:EightPointFivePercentWarrantsMember2019-12-110001477009cann:PreTriggerMembercann:Warrants15PercentMember2019-11-010001477009cann:PreTriggerMembercann:EightPointFivePercentWarrantsMember2019-11-010001477009cann:PostTriggerMembercann:Warrants15PercentMember2019-11-010001477009cann:PostTriggerMembercann:EightPointFivePercentWarrantsMember2019-11-010001477009cann:PreTriggerMembercann:Warrants15PercentMember2019-10-180001477009cann:PreTriggerMembercann:EightPointFivePercentWarrantsMember2019-10-180001477009cann:PostTriggerMembercann:Warrants15PercentMember2019-10-180001477009cann:PostTriggerMembercann:EightPointFivePercentWarrantsMember2019-10-1800014770092019-08-060001477009cann:FeinsodAgreementMember2020-01-012020-12-310001477009cann:EmployeeAwardsMember2020-01-012020-12-310001477009cann:TwoThousandTwentyCapitalRaiseMember2020-12-310001477009us-gaap:ServiceMember2020-01-012020-12-310001477009us-gaap:ProductMember2020-01-012020-12-310001477009cann:InterestIncomeRevenueMember2020-01-012020-12-310001477009cann:CultivationSalesMember2020-01-012020-12-310001477009us-gaap:ServiceMember2019-01-012019-12-310001477009us-gaap:ProductMember2019-01-012019-12-310001477009cann:InterestIncomeRevenueMember2019-01-012019-12-310001477009cann:FifteenPercentNotesMember2021-01-012021-03-310001477009cann:FifteenPercentNotesMember2020-12-012020-12-310001477009cann:SBINoteMember2019-12-302019-12-300001477009us-gaap:TradeAccountsReceivableMember2020-01-012020-12-3100014770092019-12-012019-12-010001477009srt:MinimumMemberus-gaap:LeaseholdImprovementsMember2020-01-012020-12-310001477009srt:MinimumMemberus-gaap:FurnitureAndFixturesMember2020-01-012020-12-310001477009srt:MaximumMemberus-gaap:FurnitureAndFixturesMember2020-01-012020-12-310001477009us-gaap:BuildingMember2020-01-012020-12-310001477009us-gaap:RetainedEarningsMember2020-01-012020-12-310001477009us-gaap:RetainedEarningsMember2019-01-012019-12-310001477009srt:MinimumMembercann:TwoThousandTwentyCapitalRaiseMember2020-05-292020-05-290001477009srt:MaximumMembercann:TwoThousandTwentyCapitalRaiseMember2020-05-292020-05-290001477009cann:CcrMember2020-01-012020-12-310001477009cann:FifteenPercentNotesMember2020-01-012020-03-310001477009cann:BrbRealtyMember2018-06-062018-06-060001477009cann:TotalPrincipalMember2020-12-310001477009cann:CcrMember2020-12-310001477009cann:BbMember2020-12-310001477009cann:TotalPrincipalMember2019-12-310001477009cann:CcrMember2019-12-310001477009cann:BbMember2019-12-310001477009cann:RelatedPartyNotesPayableMember2020-12-310001477009cann:TwelvePercentNotes2019Member2020-02-012020-02-290001477009us-gaap:ConvertibleNotesPayableMember2020-12-310001477009cann:SBINoteMember2019-12-300001477009us-gaap:SegmentDiscontinuedOperationsMembercann:ConsumerGoodsSegmentMember2020-01-012020-12-310001477009cann:TwentyThousandAndNineteenWarrantsMember2019-01-012019-12-310001477009us-gaap:TradeNamesMember2020-01-012020-12-310001477009us-gaap:TradeNamesMember2020-12-310001477009cann:Warrants8.5PercentMember2020-01-012020-12-310001477009cann:Warrants12PercentMember2020-01-012020-12-310001477009us-gaap:ServiceMembercann:SecuritySegmentMember2020-01-012020-12-310001477009us-gaap:ProductMembercann:ConsumerGoodsSegmentMember2020-01-012020-12-310001477009us-gaap:ServiceMembercann:SecuritySegmentMember2019-01-012019-12-310001477009us-gaap:ProductMembercann:ConsumerGoodsSegmentMember2019-01-012019-12-310001477009cann:ConsumerGoodsSegmentMember2020-12-310001477009cann:CcrMember2020-01-012020-12-310001477009cann:FifteenPercentNotesMembercann:RelatedPartyNotesPayableMember2020-12-310001477009us-gaap:InvestorMember2020-12-310001477009cann:Warrants15PercentMember2020-12-310001477009cann:Warrants12PercentMember2020-12-310001477009cann:SBINoteMember2020-12-310001477009cann:EightPointFivePercentWarrantsMember2020-12-310001477009cann:CcrMember2020-12-310001477009cann:TenPercentNotes2020Member2020-12-230001477009cann:EightPointFiveMember2020-04-300001477009cann:Warrants15PercentMember2019-12-310001477009cann:Warrants12PercentMember2019-12-310001477009cann:Warrants10percentMember2019-12-310001477009cann:CcrMember2019-03-310001477009cann:BrbRealtyMember2018-06-060001477009cann:TwelvePercentNotes2019Member2020-02-290001477009cann:FifteenPercentNotesMember2020-02-290001477009cann:TwelvePercentNotes2019Member2019-09-300001477009cann:TwelvePercentNotes2019Member2020-03-310001477009cann:FifteenPercentNotesMember2020-03-310001477009us-gaap:LoansPayableMember2020-01-080001477009cann:SBINoteMember2019-11-150001477009cann:SBINoteMember2019-11-140001477009cann:SBINoteMember2019-07-310001477009cann:CcrMember2019-05-300001477009cann:BrbRealtyMember2019-01-190001477009cann:BbMember2019-01-030001477009cann:BrbRealtyMember2018-12-130001477009cann:BrbRealtyMember2019-12-012019-12-010001477009us-gaap:InvestorMember2020-01-012020-12-310001477009cann:FeinsodAgreement2019Member2019-08-062019-08-060001477009us-gaap:ConvertibleNotesPayableMember2020-02-182020-02-180001477009cann:TwoThousandTwentyCapitalRaiseMember2020-05-292020-05-290001477009srt:MinimumMemberus-gaap:ConvertibleNotesPayableMemberus-gaap:SubsequentEventMember2021-02-080001477009srt:MaximumMemberus-gaap:ConvertibleNotesPayableMemberus-gaap:SubsequentEventMember2021-02-080001477009srt:MinimumMemberus-gaap:InvestorMember2020-12-310001477009srt:MaximumMemberus-gaap:InvestorMember2020-12-310001477009srt:MinimumMemberus-gaap:ConvertibleNotesPayableMember2020-05-290001477009srt:MinimumMemberus-gaap:ConvertibleNotesPayableMember2020-02-180001477009us-gaap:ConvertibleNotesPayableMember2020-02-180001477009cann:RelatedPartyNotePayableMember2020-12-310001477009cann:RelatedPartyNotePayableMember2020-12-230001477009cann:TwelvePercentNotes2019Member2019-12-310001477009cann:SBINoteMember2019-12-310001477009cann:RelatedPartyNotePayableMember2019-12-310001477009us-gaap:LoansPayableMemberus-gaap:PrimeRateMember2020-01-082020-01-080001477009us-gaap:LoansPayableMember2020-01-082020-01-080001477009cann:WarrantC2020Member2020-01-012020-12-310001477009cann:WarrantB2020Member2020-01-012020-12-310001477009cann:Warrant2020Member2020-01-012020-12-310001477009us-gaap:ConvertibleNotesPayableMember2020-01-012020-12-310001477009cann:EightPointFiveMember2019-06-062019-06-060001477009cann:EightPointFiveMember2019-06-060001477009cann:TwentyThousandAndNineteenWarrantsMember2019-12-310001477009cann:TenPercentNotes2020Member2020-12-310001477009cann:TwentyThousandAndNineteenWarrantsMember2019-05-310001477009us-gaap:ConvertibleNotesPayableMemberus-gaap:SubsequentEventMember2021-02-080001477009cann:Warrants10percentMember2020-12-310001477009cann:TwoThousandNineteenCapitalRaiseMember2020-12-310001477009cann:TwoThousandTwentyCapitalRaiseMember2020-12-140001477009cann:TwoThousandNineteenCapitalRaiseMember2020-05-310001477009cann:Warrants15PercentMember2020-03-3100014770092020-03-310001477009cann:TwoThousandNineteenCapitalRaiseMember2019-12-310001477009cann:FeinsodAgreement2019Member2019-08-060001477009cann:TwoThousandNineteenCapitalRaiseMember2019-05-310001477009cann:WarrantCallThresholdStockPriceMembercann:EightPointFiveMember2018-04-300001477009cann:EightPointFiveMember2018-04-3000014770092018-12-310001477009cann:DaltonAdventuresLLCMember2020-12-310001477009cann:DaltonAdventuresLLCMember2020-05-132020-05-130001477009cann:SecuritySegmentMember2020-12-310001477009cann:RelatedPartyLeaseAgreementMember2020-12-310001477009cann:SevenfiveFarmMembercann:CultivationSegmentMember2020-05-310001477009cann:TwelvePercentNotes2019Member2020-01-012020-12-310001477009cann:TenPercentNotes2020Member2020-01-012020-12-310001477009cann:FifteenPercentNotesMember2020-01-012020-12-310001477009cann:EightPointFiveMember2020-01-012020-12-310001477009cann:TwelvePercentNotes2019Member2019-01-012019-12-310001477009cann:TenPercentNotes2020Member2019-01-012019-12-310001477009cann:FifteenPercentNotesMember2019-01-012019-12-310001477009cann:EightPointFiveMember2019-01-012019-12-310001477009cann:FeinsodAgreement2019Member2020-01-012020-12-310001477009cann:EmployeeAwardsMember2020-01-012020-12-310001477009cann:ConsultingAwardsMember2020-01-012020-12-310001477009cann:FeinsodAgreement2019Member2019-01-012019-12-310001477009cann:EmployeeAwardsMember2019-01-012019-12-310001477009cann:ConsultingAwardsMember2019-01-012019-12-310001477009cann:Warrants15PercentMemberus-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310001477009cann:Warrants10percentMemberus-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310001477009cann:Warrants15PercentMemberus-gaap:AdditionalPaidInCapitalMember2019-01-012019-12-310001477009cann:Warrants12PercentMemberus-gaap:AdditionalPaidInCapitalMember2019-01-012019-12-310001477009cann:SBIWarrantsMemberus-gaap:AdditionalPaidInCapitalMember2019-01-012019-12-310001477009cann:EightPointFiveMember2018-04-012018-04-300001477009cann:Warrants15PercentMembercann:DebtDiscountMember2020-12-310001477009cann:Warrants10percentMembercann:DebtDiscountMember2020-12-310001477009cann:TenPercentNotes2020Membercann:GainLossOnDebtExtinguishmentMember2020-12-310001477009cann:FifteenPercentNotesMembercann:GainLossOnDebtExtinguishmentMember2020-12-310001477009us-gaap:ConvertibleNotesPayableMembercann:GainLossOnDebtExtinguishmentMember2020-02-180001477009us-gaap:SegmentDiscontinuedOperationsMembercann:SecuritySegmentMember2020-01-012020-12-310001477009us-gaap:SegmentDiscontinuedOperationsMembercann:SecuritySegmentMember2019-01-012019-12-310001477009us-gaap:SegmentDiscontinuedOperationsMembercann:ConsumerGoodsSegmentMember2019-01-012019-12-3100014770092020-06-3000014770092021-03-290001477009cann:TwoThousandNineteenCapitalRaiseMember2019-01-012019-12-310001477009cann:Warrant2020Member2020-12-310001477009cann:TwentyThousandAndNineteenWarrantsMember2020-12-310001477009cann:TwentyThousandAndNineteenWarrantsMember2020-02-290001477009cann:TwoThousandNineteenCapitalRaiseMember2020-01-012020-12-310001477009cann:TwoThousandTwentyCapitalRaiseMember2020-06-010001477009cann:RelatedPartyTransactionSubscriptionAgreementMember2020-06-010001477009srt:MinimumMembercann:TwoThousandTwentyCapitalRaiseMember2020-05-290001477009srt:MaximumMembercann:TwoThousandTwentyCapitalRaiseMember2020-05-290001477009cann:TwoThousandTwentyCapitalRaiseMember2020-05-290001477009us-gaap:AdditionalPaidInCapitalMember2019-01-012019-12-310001477009us-gaap:CommonStockMember2019-01-012019-12-3100014770092019-08-062019-08-060001477009cann:WarrantsWithDebtMember2020-01-012020-12-310001477009cann:ConsultingAwardsMember2020-01-012020-12-310001477009cann:IncentivePlanMember2020-01-012020-12-310001477009cann:IncentivePlanMember2018-04-012018-04-300001477009cann:WarrantsWithDebtMember2020-12-310001477009cann:ConsultingAwardsMember2020-12-310001477009us-gaap:OperatingSegmentsMembercann:OperationsMember2020-01-012020-12-310001477009us-gaap:OperatingSegmentsMembercann:CultivationMember2020-01-012020-12-310001477009us-gaap:OperatingSegmentsMembercann:CapitalInvestmentsMember2020-01-012020-12-310001477009us-gaap:IntersegmentEliminationMember2020-01-012020-12-310001477009us-gaap:OperatingSegmentsMembercann:OperationsMember2019-01-012019-12-310001477009us-gaap:OperatingSegmentsMembercann:CapitalInvestmentsMember2019-01-012019-12-310001477009cann:RelatedPartyConsultingServicesAgreementMember2020-06-032020-06-030001477009cann:RelatedPartyConsultingServicesAgreementMember2020-01-012020-12-3100014770092021-02-012021-02-280001477009cann:TwentyThousandAndNineteenWarrantsMember2019-05-312019-05-310001477009cann:RelatedPartyLeaseAgreementMember2020-01-012020-12-310001477009cann:CommercialRealEstateLeaseMember2023-12-310001477009srt:ScenarioForecastMembercann:CommercialRealEstateLeaseMember2022-12-310001477009srt:ScenarioForecastMembercann:CommercialRealEstateLeaseMember2021-12-310001477009cann:FifteenPercentNotesMember2020-02-012020-03-310001477009cann:TwentyThousandAndNineteenWarrantsMember2020-02-012020-02-290001477009cann:SevenfiveFarmMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMembercann:CultivationSegmentMember2020-01-012020-12-310001477009cann:NextBigCropMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001477009cann:NextBigCropMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-12-3100014770092020-12-232020-12-230001477009cann:Warrant2020Member2020-12-012020-12-310001477009cann:TwentyThousandAndNineteenWarrantsMember2020-01-012020-12-310001477009cann:CommercialRealEstateLeaseMember2020-05-132020-05-130001477009cann:CommercialRealEstateLeaseMember2020-12-310001477009cann:CommercialRealEstateLeaseMember2020-05-130001477009cann:RelatedPartyNotesPayableMember2020-01-012020-12-310001477009cann:CommercialRealEstateLeaseMember2020-12-012020-12-310001477009us-gaap:EmployeeStockOptionMember2020-01-012020-12-310001477009cann:Warrants12PercentMember2019-01-012019-12-310001477009cann:SBIWarrantsMember2019-01-012019-12-310001477009cann:Warrants15PercentMember2020-01-012020-12-310001477009cann:Warrants15PercentMember2019-01-012019-12-310001477009cann:ConsumerGoodsSegmentMember2020-01-012020-12-310001477009cann:ConsumerGoodsSegmentMember2019-12-310001477009cann:ConsumerGoodsSegmentMember2019-01-012019-12-310001477009cann:SecuritySegmentMember2019-12-310001477009cann:SecuritySegmentMember2020-01-012020-12-310001477009cann:SecuritySegmentMember2019-01-012019-12-310001477009us-gaap:EmployeeStockOptionMemberus-gaap:CommonStockMember2020-01-012020-12-310001477009cann:FifteenPercentNotesMember2019-12-310001477009cann:TwelvePercentNotes2019Member2019-09-012019-09-300001477009cann:TwoThousandTwentyCapitalRaiseMember2020-10-040001477009srt:MaximumMemberus-gaap:ConvertibleNotesPayableMemberus-gaap:SubsequentEventMember2021-02-082021-02-080001477009us-gaap:ConvertibleNotesPayableMemberus-gaap:SubsequentEventMember2021-02-082021-02-080001477009srt:MaximumMemberus-gaap:InvestorMember2020-01-012020-12-310001477009cann:Warrants10percentMember2020-01-012020-12-310001477009us-gaap:EmployeeStockOptionMember2020-12-310001477009cann:TwoThousandTwentyCapitalRaiseMember2020-12-142020-12-140001477009cann:TwoThousandTwentyCapitalRaiseMember2020-01-012020-12-310001477009cann:TwoThousandNineteenCapitalRaiseMember2019-05-312019-05-310001477009cann:TwoThousandAndTwentyWarrantsMember2020-12-012020-12-310001477009us-gaap:CommonStockMember2020-01-012020-12-310001477009cann:DaltonAdventuresLLCMember2020-05-130001477009us-gaap:OperatingSegmentsMembercann:OperationsMember2020-12-310001477009us-gaap:OperatingSegmentsMembercann:CultivationMember2020-12-310001477009us-gaap:OperatingSegmentsMembercann:CapitalInvestmentsMember2020-12-310001477009us-gaap:OperatingSegmentsMember2020-12-310001477009us-gaap:IntersegmentEliminationMember2020-12-310001477009us-gaap:CorporateMember2020-12-310001477009us-gaap:OperatingSegmentsMembercann:OperationsMember2019-12-310001477009us-gaap:OperatingSegmentsMembercann:CapitalInvestmentsMember2019-12-310001477009us-gaap:OperatingSegmentsMember2019-12-310001477009us-gaap:CorporateMember2019-12-3100014770092019-01-012019-12-310001477009cann:FifteenPercentNotesMember2020-12-310001477009us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310001477009us-gaap:EmployeeStockOptionMember2020-02-182020-02-180001477009us-gaap:EmployeeStockOptionMemberus-gaap:CommonStockMember2020-12-3100014770092020-12-310001477009us-gaap:EmployeeStockOptionMemberus-gaap:CommonStockMember2019-12-3100014770092019-12-3100014770092020-01-012020-12-31cann:segmentcann:Yxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:purecann:itemcann:customercann:EquityInstrumentsutr:sqftcann:D

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2020

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________

Commission file number:  000-54457

GENERAL CANNABIS CORP

(Exact name of registrant as specified in its charter)

COLORADO

    

90-1072649

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

6565 E. Evans Avenue
Denver, Colorado 80224

(Address of principal executive offices)

Registrant’s telephone number, including area code: (303) 759-1300

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Name of each exchange on which registered

Ticker symbol

N/A

N/A

N/A

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes    No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes    No

Indicate by check mark whether the registrant (1) has filed all reports to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes    No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulations S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes    No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act):  Yes    No

The aggregate market value of the voting stock held by non-affiliates of the registrant, based upon the closing sale price of the registrant’s common stock on June 30, 2020, was $21,883,111.

As of March 29, 2021, the Registrant had 62,146,515 issued and outstanding shares of common stock.

DOCUMENTS INCORPORATED BY REFERENCE

Part III of this Annual Report on Form 10-K incorporates by reference information (to the extent specific sections are referred to in this Report) from the registrant’s Proxy Statement for its 2021 Annual Meeting of Stockholders

TABLE OF CONTENTS

PART I

Item 1.

Business

4

Item 1A.

Risk Factors

11

Item 1B.

Unresolved Staff Comments

24

Item 2.

Properties

24

Item 3.

Legal Proceedings

24

Item 4.

Mine Safety Disclosures

24

PART II

Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

25

Item 6.

Selected Financial Data

25

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

25

Item 7A.

Quantitative and Qualitative Disclosures about Market Risk

32

Item 8.

Financial Statements and Supplementary Data

33

Item 9.

Changes In and Disagreements With Accountants On Accounting and Financial Disclosure

70

Item 9A.

Controls and Procedures

71

Item 9B.

Other Information

72

PART III

Item 10.

Directors, Executive Officers and Corporate Governance

73

Item 11.

Executive Compensation

73

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

73

Item 13.

Certain Relationships and Related Transactions and Director Independence

73

Item 14.

Principal Accounting Fees and Services

73

PART IV

Item 15.

Exhibits and Financial Statement Schedules

74

Signatures

77

2

PART I

CAUTIONARY STATEMENT ON FORWARD-LOOKING INFORMATION

This Annual Report on Form 10-K (this “Report”) contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements discuss matters that are not historical facts. Because they discuss future events or conditions, forward-looking statements may include words such as “anticipate,” “believe,” “estimate,” “intend,” “could,” “should,” “would,” “may,” “seek,” “plan,” “might,” “will,” “expect,” “predict,” “project,” “forecast,” “potential,” “continue” negatives thereof or similar expressions. Forward-looking statements speak only as of the date they are made, are based on various underlying assumptions and current expectations about the future and are not guarantees. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, level of activity, performance or achievement to be materially different from the results of operations or plans expressed or implied by such forward-looking statements.

We cannot predict all risks and uncertainties. Accordingly, such information should not be regarded as representations that the results or conditions described in such statements will occur or that our objectives and plans will be achieved and we do not assume any responsibility for the accuracy or completeness of any of these forward-looking statements. These forward-looking statements are found at various places throughout this Report and include information concerning possible or assumed future results of our operations, including statements about potential acquisition or merger targets; business strategies; future cash flows; financing plans; plans and objectives of management, any other statements regarding future acquisitions, future cash needs, future operations, business plans and future financial results, and any other statements that are not historical facts.

Some factors that might cause such differences are described in the section entitled “Risk Factors” in this Report and in other documents that we file from time to time with the Securities and Exchange Commission (“SEC”), which factors include, without limitation, the following:

Competition from other similar companies;
Regulatory limitations on the products or services we can offer and markets we can serve;
Other changes in the regulation of medical and recreational cannabis use;
Changes in underlying consumer behavior, which may affect the business of our customers;
Our ability to access adequate financing on reasonable terms and our ability to raise additional capital in order to fund our operations;
Our ability to identify and successfully integrate acquisitions, and the ability of acquired businesses to perform as expected;
Challenges with new products, services and markets; and
Fluctuations in the credit markets and demand for credit.

These forward-looking statements represent our intentions, plans, expectations, assumptions and beliefs about future events and are subject to risks, uncertainties and other factors. Many of those factors are outside of our control and could cause actual results to differ materially from the results expressed or implied by those forward-looking statements. In light of these risks, uncertainties and assumptions, the events described in forward-looking statements might not occur or might occur to a different extent or at a different time than we have described. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Report. All subsequent written and oral forward-looking statements concerning other matters addressed in this Report and attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this Report.

Except to the extent required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or otherwise.

3

The following description of the business of General Cannabis Corp should be read in conjunction with the information included elsewhere in this Report. Unless the context indicates otherwise, references to the words “we,” “us,” “our,” “GCC,” and the “Company” in this Report refer to General Cannabis Corp.

ITEM 1. BUSINESS.

Business Strategy

The cannabis industry is dynamic and becoming more mature. As markets like Colorado mature, we believe that an opportunity exists for operationally excellent companies to build scale by acquiring and operating licensed cannabis businesses. Accordingly, we are focused on: (1) identifying licensed cannabis assets that we can acquire, (2) focusing on execution, which will allow us to continue to generate cash and meet our financial commitments and, (3) moving with an urgency that reflects our conviction and confidence in our ability to create the customers’ loyalty and advocacy. To that end, during the years ended 2020 and 2019, we implemented the following significant actions in support of our continued growth:

On May 4, 2020, we received a Suitability Approval from the Colorado Marijuana Enforcement Division (“MED”), becoming one of the first, and to date, one of the only public companies pre-approved to acquire licensed cannabis facilities.
On May 13, 2020, we received approval of the transaction and transfer of the Dalton Adventures, LLC (“Seller”) license from the Colorado Marijuana Enforcement Division (“the MED”). On May 25, 2020, we finalized the acquisition, pursuant to which we acquired the assets of the Seller that constitute the business of SevenFive Farm, a cultivation facility located in Boulder, Colorado. The purchase price paid by the Company to the Seller was 8,859,117 shares of common stock. Barker Dalton, the sole member and owner of Dalton Adventures, LLC, joined our Board of Directors in September 2020.

On May 29, 2020, we entered into a subscription agreement, as amended with Hershey Strategic Capital, LP and Shore Ventures III, LP (collectively the “Hershey Investor”) with respect to the sale of shares of common stock and warrants to purchase common stock. During the year ended December 31, 2020, we sold $3,000,000 of securities to the Hershey Investor, representing 7,532,010 shares of common stock and warrants to purchase 5,649,007 shares of common stock with an exercise price of $0.5565 per share. In accordance with the terms of the subscription agreement, we issued an additional 1,631,000 warrants in December 2020 to purchase common stock with an exercise price of $0.4917 to the Hershey Investor. As part of these transactions, Adam Hershey joined our Board of Directors in July 2020.

In September 2020, we added to the strength of our Board of Directors by adding Carl Williams as Chairman and Independent Director, Richard Travia as Independent Director and Barker Dalton as Director.
On December 23, 2020 and February 8, 2021, the Company entered into a Securities Purchase Agreement with each of certain accredited investors, pursuant to which the Company issued and sold senior convertible promissory notes (the “Notes”) with an aggregate principal amount of $4,600,000 in exchange for payment to the Company by certain investors of an aggregate amount of $3,600,000 in cash, as well as cancellation of outstanding indebtedness in the aggregate amount of $1,000,000 represented by certain of the prior promissory notes issued by the Company in February 2020 to certain other Investors.  In connection with the issuance of the Notes, the holders received warrants to purchase shares of the Company’s common stock equal to 20% coverage of the aggregate principal amount at $0.56 per share. The Notes bear interest at an annual rate of 10%. Notes with an aggregate principal amount of $2,940,000 will mature on December 23, 2023 and Notes with an aggregate principal amount of $1,660,000 will mature on February 8, 2024. The Investors have the option at any time to convert up to 50% of the outstanding unpaid principal and accrued interest of the Notes into the Company’s common stock at a variable price of 80% of the market price but no less than $0.65 per share and no more than $1.00 per share. 
On December 26, 2019, the Board of Directors and management made the strategic decision to investigate a possible buyer for our Security Segment and if no buyer could be found, cease operations of the Security

4

Segment. We transferred all our Colorado security contracts and employees to a company on January 16, 2020. On February 6, 2020 we cancelled all our security contracts in California.

On December 26, 2019, the Board of Directors and management made the strategic decision to cease operations of Chiefton, our apparel line.

On December 26, 2019, the Board of Directors and management committed to a plan to cease operations of STOA Wellness, our retail CBD store. We transferred all assets of STOA Wellness to an individual on January 10, 2020, in exchange for the release on the outstanding lease.

We determined the sale and disposal of our security and consumer goods segments represented a strategic shift that had a significant effect on our results of operations and, as a result, we have presented the disposal as held for sale and discontinued operations in our financial statements. Unless noted otherwise, discussion in this Annual Report on Form 10-K pertains to our continuing operations.

History and Corporate Structure

General Cannabis Corp, a Colorado corporation, was incorporated on June 3, 2013. We operate through our eight wholly-owned subsidiaries: (a) 6565 E. Evans Owner LLC, a Colorado limited liability company formed in 2014; (b) General Cannabis Capital Corporation, a Colorado corporation formed in 2015; (c) GC Security LLC (“GCS”), a Colorado limited liability company formed in 2015; (d) GC-NY Health, LLC, a New York limited liability company formed in 2019; (e) Standard Cann, Inc., a Colorado corporation formed in 2019; (f) SevenFive Farm, LLC, a limited liability company formed in 2020, (g) SevenFive Farm Cultivation, LLC, a limited liability company formed in 2020 and (h) GC Corp., a Colorado corporation, originally formed in 2013 under the name ACS Corp. In 2015, the name was changed to GC Corp.

Our Products, Services and Customers

Through our reporting segments (Operations, Cultivation, and Investments), we provide products, services and capital to the regulated cannabis industry and non-cannabis customers, which include the following:

Operations Consulting and Products (“Operations Segment”)

Through Next Big Crop (“NBC”), we deliver comprehensive consulting services to the cannabis industry that include obtaining licenses, compliance, cultivation, retail operations, logistical support, facility design and construction, and expansion of existing operations. During 2020 and 2019, 62% and 59% of NBC’s revenue was from four customers and three customers, respectively.

NBC oversees our wholesale equipment and supply business, operated under the name “GC Supply,” which provides turnkey sourcing and stocking services to cultivation, retail and infused products manufacturing facilities. Our products include building materials, equipment, consumables and compliance packaging. There are generally multiple suppliers for the products we sell; however, there are a limited number of manufacturers of certain high-tech cultivation equipment.

NBC provides a competitive advantage as we plan to evaluate and operate licensed cultivation facilities.

Cultivation (“Cultivation Segment”)

Through our acquisition of SevenFive Farm ("SevenFive") in May 2020, we operate a licensed light deprivation greenhouse cultivation facility. During 2020, 28% of SevenFive Farm’s revenue was from two customers.

Capital Investments and Real Estate (“Investments Segment”)

5

We may provide debt or equity capital to cannabis businesses through investing in businesses using cash or shares of our common stock.

Competitive Strengths

We believe we possess certain competitive strengths and advantages in the industries in which we operate:

Cultivation Expertise. NBC has designed and operated cultivation facilities across the country. As we execute on our rollup strategy, this expertise enables us to evaluate, acquire and operate these facilities efficiently.

Range of Services. We are able to leverage our breadth of services and resources to deliver comprehensive, integrated solutions to companies in the cannabis industry—from operational and compliance, to products and services.

Strategic Alliances. We are dedicated to growing through strategic acquisitions, partnerships and agreements that will enable us to enter and expand into new markets. Our strategy is to pursue alliances with potential targets that have the ability to generate positive cash flow, effectively meet customer needs and supply desirable products, services or technologies, among other considerations. We anticipate that strategic alliances will play a significant role as more states pass legislation permitting the cultivation and sale of hemp and cannabis.

Regulatory Compliance. The state and local laws regulating the cannabis industry change at a rapid pace. We have resources committed to ensure our operations are in compliance with all state and local laws, policies, guidance and regulations to which we are subject. We apply this compliance knowledge to our customers in order to ensure that they, too, are in full compliance.

Industry Knowledge. We continue to create, share and leverage information and experiences with the purpose of creating awareness and identifying opportunities to increase shareholder value. Our management team has business expertise, extensive knowledge of the cannabis industry and closely monitors changes in legislation. We work with partners who enhance the breadth of our industry knowledge.

Competition

Overall, we believe we have a competitive advantage by providing a range of goods and services to the cannabis industry. This allows us to provide integrated solutions to our customers, as well as sell additional goods and services to customers of a single segment. There is no aspect of our business, however, that is protected by patents or copyrights.

Operations Consulting and Products. There are a limited number of competitors that provide the full range of services that NBC delivers. However, each individual service we provide has competition from experts in individual, specific fields. For example, attorneys may assist with license procurement and compliance. There are numerous firms that specialize in traditional greenhouse and cultivation consulting, as well as companies that provide operations services. As the cannabis industry grows, these competitors may develop further expertise and expand their focus on the cannabis industry.

Cultivation. The Colorado cultivation market is highly fragmented. There are over one million cannabis plants cultivated for cannabis sales each year and a typical 15,000 to 20,000 square foot grow facility contains approximately 5,000 to 7,500 plants. We believe that there is a significant opportunity to identify and acquire additional cultivation assets, which will ultimately supply our own proprietary brands and retail locations.

Capital Investments and Real Estate. Because cannabis is still illegal at the federal level, many banks and traditional financial institutions refuse to provide financial services to cannabis-related business. With the growth of the cannabis industry, however, there has been growth in alternative financing and banking resources. Many of these alternative sources have more capital and resources than we have.

6

Government and Industry Regulation

Cannabis is currently a Schedule I controlled substance under the Controlled Substances Act (“CSA”) and is, therefore, illegal under federal law. Even in those states in which the use of cannabis has been legalized pursuant to state law, its use, possession and/or cultivation remains a violation of federal law. A Schedule I controlled substance is defined as one that has no currently accepted medical use in the United States, a lack of safety for use under medical supervision and a high potential for abuse. The U.S. Department of Justice (the “DOJ”) describes Schedule I controlled substances as “the most dangerous drugs of all the drug schedules with potentially severe psychological or physical dependence.” If the federal government decides to enforce the CSA in Colorado with respect to state-regulated cannabis activities in Colorado and other states, persons that are charged with distributing, possessing with intent to distribute or growing cannabis could be subject to fines and/or terms of imprisonment, the maximum being life imprisonment and a $50 million fine.

In light of the conflict between federal laws and state laws regarding cannabis, the administration under President Obama had effectively stated that it was not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by state-designated laws allowing the use and distribution of medical cannabis. For example, the prior DOJ Deputy Attorney General of the Obama administration, James M. Cole, issued a memorandum (the “Cole Memo”) to all United States Attorneys providing updated guidance to federal prosecutors concerning cannabis enforcement under the CSA. In addition, the Financial Crimes Enforcement Network (“FinCEN”) provided guidelines (the “FinCEN Guidelines”) on February 14, 2014, regarding how financial institutions can provide services to cannabis-related businesses consistent with their Bank Secrecy Act (“BSA”) obligations (see “-- FinCEN”). The policies of the Obama administration concerning federal law enforcement regarding cannabis, notwithstanding the rescission of the Cole Memo (see below), were continued during the Trump administration and we expect them to be continued during the Biden administration.

Congress previously enacted an omnibus spending bill that included a provision (the “Rohrabacher-Blumenauer Amendment”) prohibiting the DOJ from using funds to prevent states with medical cannabis laws from implementing such laws. This provision is renewed annually by Congress and is current through September 30, 2021. In August 2016, a Ninth Circuit federal appeals court ruled in United States v. McIntosh that the Rohrabacher-Blumenauer Amendment bars the DOJ from spending funds on the prosecution of conduct that is allowed by state medical cannabis laws, provided that such conduct is in strict compliance with applicable state law. In March 2015, bipartisan legislation titled the Compassionate Access, Research Expansion, and Respect States Act (the “CARERS Act”) was introduced, proposing to allow states to regulate the medical use of cannabis by changing applicable federal law, including by reclassifying cannabis under the Controlled Substances Act to a Schedule II controlled substance and thereby changing the plant from a federally-criminalized substance to one that has recognized medical uses. More recently, the Respect State Marijuana Laws Act of 2017 has been introduced in the U.S. House of Representatives, which proposes to exclude persons who produce, possess, distribute, dispense, administer or deliver marijuana in compliance with state laws from the regulatory controls and administrative, civil and criminal penalties of the CSA.

These developments previously were met with a certain amount of optimism in the cannabis industry, but (i) neither the CARERS Act nor the Respect State Marijuana Laws Act of 2017 have yet been adopted, (ii) the Rohrabacher-Blumenauer Amendment, being an amendment to an appropriations bill that must be renewed annually, has not currently been renewed beyond September 30, 2021, and (iii) the ruling in United States v. McIntosh is only applicable precedent in the Ninth Circuit, which does not include Colorado, the state where we currently primarily operate.

Furthermore, on January 4, 2018, the former U.S. Attorney General, Jeff Sessions, issued a memorandum for all U.S. Attorneys (the “Sessions Memo”) stating that the Cole Memo was rescinded effectively immediately. In particular, Mr. Sessions stated that “prosecutors should follow the well-established principles that govern all federal prosecutions,” which require “federal prosecutors deciding which cases to prosecute to weigh all relevant considerations, including federal law enforcement priorities set by the Attorney General, the seriousness of the crime, the deterrent effect of criminal prosecution, and the cumulative impact of particular crimes on the community.” The Sessions Memo went on to state that given the DOJ’s well-established general principles, “previous nationwide guidance specific to marijuana is unnecessary and is rescinded, effective immediately.”

7

In response to the Sessions Memo, U.S. Attorney Bob Troy for the District of Colorado, the state in which our principal business operations are presently located, issued a statement on January 4, 2018, stating that the United States Attorney’s Office in Colorado is already guided by the well-established principles referenced in the Sessions Memo, “focusing in particular on identifying and prosecuting those who create the greatest safety threats to our communities around the state. We will, consistent with the Attorney General’s latest guidance, continue to take this approach in all of our work with our law enforcement partners throughout Colorado.”

It is unclear at this time whether the Sessions Memo will be rescinded by the Biden administration; nor is it clear whether the Biden administration will strongly enforce the federal laws applicable to cannabis or what types of activities will be targeted for enforcement. However, a significant change in the federal government’s enforcement policy with respect to current federal laws applicable to cannabis could cause significant financial damage to us. We currently cultivate, distribute and sell cannabis. We may be irreparably harmed by a change in enforcement policies of the federal government depending on the nature of such change. As of the date of this Report, we have provided products and services to state-approved cannabis cultivators and dispensary facilities. Accordingly, we could be subject to criminal prosecution, which could lead to imprisonment and/or the imposition of penalties, fines, or forfeiture.

Recent 2019 legislative proposals have been introduced:

Sensible Enforcement of Cannabis Act. This would protect cannabis businesses and consumers in states where cannabis has been legalized, while continuing the federal cannabis prohibition to remain in place in states where cannabis has not been legalized.
Marijuana Revenue and Regulation Act. This would create a nationwide regulatory structure for legalizing cannabis and removing it from the CSA.
SAFE Banking Act. This would protect financial institutions that offer services to state-legal cannabis-related businesses.
Marijuana Opportunity, Reinvestment and Expungement Act (MORE Act). This would end the criminalization of cannabis at the federal level by removing it from the list of controlled substances in the CSA, as well as eliminating related criminal penalties.

None of the above proposals have been enacted; and while the Biden administration appears to have a more friendly position toward legalization of cannabis generally than the Trump administration, it cannot presently be determined what position the current administration will take on either of these proposals.

The Cole Memo

Because of the discrepancy between the laws in some states, which permit the distribution and sale of medical and recreational cannabis, from federal law that prohibits any such activities, DOJ Deputy Attorney General James M. Cole issued the Cole Memo concerning cannabis enforcement under the CSA.

At the time of its issuance, the Cole Memo reiterated Congress’s determination that cannabis is a dangerous drug and that the illegal distribution and sale of cannabis is a serious crime that provides a significant source of revenue to large-scale criminal enterprises, gangs, and cartels. The Cole Memo noted that the DOJ was committed to enforcement of the CSA consistent with those determinations. It also noted that the DOJ was committed to using its investigative and prosecutorial resources to address the most significant threats in the most effective, consistent, and rational way. In furtherance of those objectives, the Cole Memo provided guidance to DOJ attorneys and law enforcement to focus their enforcement resources on persons or organizations whose conduct interferes with any one or more of the following important priorities (the “Enforcement Priorities”) in preventing:

the distribution of cannabis to minors;
revenue from the sale of cannabis from going to criminal enterprises, gangs, and cartels;

8

the diversion of cannabis from states where it is legal under state law in some form to other states;
state-authorized cannabis activity from being used as a cover or pretext for the trafficking of other illegal drugs or other illegal activity;
violence and the use of firearms in the cultivation and distribution of cannabis;
drugged driving and the exacerbation of other adverse public health consequences associated with cannabis use;
the growing of cannabis on public lands and the attendant public safety and environmental dangers posed by cannabis production on public lands; and
cannabis possession or use on federal property.

Although the Sessions Memo has rescinded the Cole Memo and it is unclear at this time what the ultimate impact of that rescission will have on our business, if any, we intend to continue to conduct rigorous due diligence to verify the legality of all activities that we engage in and ensure that our activities do not interfere with any of the Enforcement Priorities set forth in the Cole Memo.

FinCEN

FinCEN provided guidance regarding how financial institutions can provide services to cannabis-related businesses consistent with their BSA obligations. For purposes of the FinCEN guidelines, a “financial institution” includes any person doing business in one or more of the following capacities:

bank (except bank credit card systems);
broker or dealer in securities;
money services business;
telegraph company;
card club; and
a person subject to supervision by any state or federal bank supervisory authority.

In general, the decision to open, close, or refuse any particular account or relationship should be made by each financial institution based on a number of factors specific to that institution. These factors may include its particular business objectives, an evaluation of the risks associated with offering a particular product or service, and its capacity to manage those risks effectively. Thorough customer due diligence is a critical aspect of making this assessment.

In assessing the risk of providing services to a cannabis-related business, a financial institution should conduct customer due diligence that includes: (i) verifying with the appropriate state authorities whether the business is duly licensed and registered; (ii) reviewing the license application (and related documentation) submitted by the business for obtaining a state license to operate its cannabis-related business; (iii) requesting from state licensing and enforcement authorities available information about the business and related parties; (iv) developing an understanding of the normal and expected activity for the business, including the types of products to be sold and the type of customers to be served (e.g., medical versus recreational customers); (v) ongoing monitoring of publicly available sources for adverse information about the business and related parties; (vi) ongoing monitoring for suspicious activity, including for any of the red flags described in this guidance; and (vii) refreshing information obtained as part of customer due diligence on a periodic basis and commensurate with the risk. With respect to information regarding state licensure obtained in connection with such customer due diligence, a financial institution may reasonably rely on the accuracy of information provided by state licensing authorities, where states make such information available.

As part of its customer due diligence, a financial institution should consider whether a cannabis-related business implicates one of the Cole Memo Enforcement Priorities or violates state law. This is a particularly important factor for a financial institution to consider when assessing the risk of providing financial services to a cannabis-related business. Considering this factor also enables the financial institution to provide information in BSA reports pertinent to law enforcement’s priorities. A financial institution that decides to provide financial services to a cannabis-related business would be required to file suspicious activity reports. It is unclear at this time what impact the Sessions Memo will have on customer due diligence by a financial institution.

9

While we believe we do not qualify as a financial institution in the United States, we cannot be certain that we do not fall under the scope of the FinCEN guidelines. We plan to use the FinCEN Guidelines, as may be amended, as a basis for assessing our relationships with potential tenants, clients and customers. As such, as we engage in financing activities, we intend to adhere to the guidance of FinCEN in conducting and monitoring our financial transactions. Because this area of the law is uncertain and is expected to evolve rapidly, we believe that FinCEN’s guidelines will help us best operate in a prudent, reasonable and acceptable manner. There is no assurance, however, that our activities will not violate some aspect of the CSA. If we are found to violate the federal statute or any other in connection with our activities, our company could face serious criminal and civil sanctions.

Moreover, since the use of cannabis is illegal under federal law, we may have difficulty acquiring or maintaining bank accounts and insurance, and our stockholders may find it difficult to deposit their stock with brokerage firms.

Licensing and Local Regulations

Where applicable, we apply for state licenses or similar approvals that are necessary to conduct our business in compliance with local laws. Our subsidiary, GC Corp., has been registered with the MED as an approved vendor since September 8, 2014. GCS, another subsidiary, has been registered as a MED approved vendor since March 11, 2015.

On May 1, 2020, the MED granted regulatory approval to the Company as a qualified and suitable buyer of licensed cannabis operations in the State. This authorization, known as a Suitability Approval, establishes the Company as one of the first public companies authorized to acquire licensed cultivation, manufacturing and retail operations throughout Colorado.

Local laws at the county and municipal level add an additional layer of complexity to legalized cannabis. Despite a state’s adoption of legislation legalizing cannabis, counties and municipalities within the state may have the ability to otherwise restrict cannabis activities, including but not limited to cultivation, retail, distribution, manufacturing or consumption.

Zoning sets forth the approved use of land in any given city, county or municipality. Zoning is set by local governments or local voter referendum, and may otherwise be restricted by state laws. For example, under certain state laws a seller of liquor may not be allowed to operate within 1,000 feet of a school. There may be similar restrictions imposed on cannabis operators, which will restrict where cannabis operations may be located and the manner and size to which they can grow and operate. Zoning can be subject to change or withdrawal, discretionary approvals may be required for certain uses, and properties can be re-zoned. The zoning of our properties will have a direct impact on our business operations.

Human Capital

We are managed and operated by the Board of Directors and executive officers of General Cannabis Corp. As of December 31, 2020, we had 43 full-time employees. Executing our strategic vision requires that we attract and retain the best talent. The Company must appropriately reward high-performers and offer competitive benefits.  The Company offers comprehensive benefits, including medical, dental and vision insurance for employees, their spouses or domestic partners, and their dependents. We also provide retirement programs, life insurance, family assistance, short-term disability and paid vacation and sick time. As a people-first company rooted in values, our purpose of cultivating an inclusive environment means hiring world-class individuals dedicated to fostering a culture that champions diversity, ensures equity, and celebrates inclusion. We provide opportunities for our employees to drive our strategy by creating programs that raise awareness, allowing courageous conversations and a more inclusive culture.

Corporate Contact Information

Our principal executive offices are located at 6565 E. Evans Avenue, Denver, Colorado 80224; Telephone No.: (303) 759-1300. Our website is http://www.generalcann.com. The content on our website is available for informational purposes only. It should not be relied upon for investment purposes, nor is it incorporated by reference into this Form 10-K.

10

Available Information

We maintain a website at www.generalcann.com and make available, free of charge, on our website, our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K (including any amendments thereto), registration statements and other information filed with, or furnished to, the SEC, as soon as reasonably practicable after such documents are so filed or furnished, as well as our Code of Ethics. Any materials we file with the SEC, including our annual reports, quarterly reports, current reports, proxy statements, information statements and other information, are also available at the SEC’s Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC at http://www.sec.gov.

Information about our Executive Officers

Our executive officers, with their ages and the offices held as of March 31, 2021, are as follows:

Name

 

Age

Positions

Steven D. Gutterman

 

51

Chief Executive Officer and Director

Diane Jones

 

56

Chief Financial Officer

Steve Gutterman was appointed a director and as our Chief Executive Officer on December 13, 2019. Mr. Gutterman is a member of the Corporate Governance and Nominating Committee.  Mr. Gutterman has more than two decades of experience leading high growth businesses in highly regulated industries. Most recently, Mr. Gutterman served as President of Harvest Health & Recreation, one of the largest cannabis multi-state operators in the US, where he led the company’s public offering and led its global operations. Prior to that, he served as Chief Executive Officer of market research company Mobile Accord and before that as Executive Vice President and Chief Operating Officer of E*TRADE Bank, a $35 billion federally regulated thrift. Mr. Gutterman holds a JD/MBA from Columbia University and BA Cum Laude in Political Science from Tufts University.

Diane Jones was appointed our Chief Financial Officer and Principal Financial Officer and Principal Accounting Officer on September 13, 2020. Prior to her appointment, since 2015 Ms. Jones owned her own consulting firm, where she provided accounting and finance consulting services to numerous public and private companies. While consulting, Ms. Jones was responsible for her clients’ accounting and valuation for business mergers, acquisitions and divestitures, Securities and Exchange Commission filings, technical accounting and process improvements. Ms. Jones served as Senior Director of Shared Financial Services of Arrow Electronics, Inc. from 2010 to 2013 and as Worldwide Controller of Arrow Electronics Computing Solutions, a division of Arrow Electronics, Inc., from 2008 to 2009, where she was responsible for back office accounting operations, acquisition integration, and oversight of accounting functions. Prior to that, Ms. Jones served as Assistant Corporate Controller of Ball Corporation, a public packaging company, where she was responsible for SEC filings, Sarbanes-Oxley compliance, management reporting and oversight of all accounting functions. Ms. Jones also has eight years of experience as an auditor with big four audit firms as a senior manager, serving both public and private companies. She is a licensed certified public accountant in the state of Colorado and holds a BBA degree in marketing from Texas A&M University and an MBA with an emphasis in accounting from the University of Houston.

ITEM 1A. RISK FACTORS.

Investing in our common stock involves a high degree of risk. You should carefully consider the following risks and all other information contained in this Form 10-K, including our consolidated financial statements and the related notes, before investing in our common stock. The risks and uncertainties described below are not the only ones we face, but include the most significant factors currently known by us that make investing in our common stock speculative or risky. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, also may become important factors that affect us. If any of the following risks materialize, our business, financial condition and results of operations could be materially harmed. In that case, the trading price of our common stock could decline, and you may lose some or all of your investment.

11

Risks Related to Our Business and Industry

We have a limited operating history in an evolving industry, which makes it difficult to accurately assess our future growth prospects.

We operate in an evolving industry that may not develop as expected. Furthermore, our operations continue to evolve under our business plan as we continually assess new strategic opportunities for our business within our industry. Assessing the future prospects of our business is challenging in light of both known and unknown risks and difficulties we may encounter. Growth prospects in our industry can be affected by a wide variety of factors including:

Competition from other similar companies;
Regulatory limitations on the products we can offer and markets we can serve;
Other changes in the regulation of medical and recreational cannabis use;
Changes in underlying consumer behavior, which may affect the business of our customers;
Our ability to access adequate financing on reasonable terms and our ability to raise additional capital in order to fund our operations;
Challenges with new products, services and markets; and
Fluctuations in the credit markets and demand for credit.

 

We may not be able to successfully address these factors, which could negatively impact our growth, harm our business and cause our operating results to be worse than expected.

We have a history of losses and may not achieve profitability in the future.

We generated net losses of approximately $7.7 million and $15.5 million, respectively, in the years ended December 31, 2020 and 2019. As of December 31, 2020, we had an accumulated deficit of approximately $75 million. We will need to generate and sustain increased revenues in future periods in order to become profitable, and, even if we do, we may not be able to maintain or increase any such level of profitability.

As we grow, we expect to continue to expend substantial financial and other resources on:

personnel, including significant increases to the total compensation we pay our employees as we grow our employee headcount;
expenses relating to increased marketing efforts;
strategic acquisitions of businesses and real estate; and
general administration, including legal, accounting and other compliance expenses related to being a public company.

These expenditures are expected to increase and may adversely affect our ability to achieve and sustain profitability as we grow. Our efforts to grow our business may also be more costly than we expect, and we may not be able to increase our revenues enough to offset our higher operating expenses. We may incur losses in the future for a number of reasons, including the other risks described in this Report, unforeseen expenses, difficulties, complications and delays and other unknown events. If we are unable to achieve and sustain profitability, the market price of our common stock may significantly decrease.

Cannabis remains illegal under federal law, and any change in the enforcement priorities of the federal government could render our current and planned future operations unprofitable or even prohibit such operations.

The cultivation, manufacture, distribution, and possession of marijuana is illegal under U.S. federal law. The Supremacy Clause of the United States Constitution establishes that the US Constitution and federal laws made pursuant to it are paramount and, in case of conflict between federal and state law, the federal law must be applied. Accordingly, federal law applies even in those states in which the use of marijuana has been legalized. Enforcement of federal law regarding marijuana would harm our business, prospects, results of operation, and financial condition.

12

The United States federal government regulates drugs through the Controlled Substances Act (the “CSA”), which places controlled substances, including cannabis, on one of five schedules. Cannabis is currently classified as a Schedule I controlled substance, which is viewed as having a high potential for abuse and having no currently accepted medical use in treatment in the United States. No prescriptions may be written for Schedule I substances, and such substances are subject to production quotas imposed by the United States Drug Enforcement Administration (the “DEA”). Because of this, doctors may not prescribe cannabis for medical use under federal law, although they can recommend its use under the First Amendment.

Currently, numerous U.S. states, the District of Columbia and U.S. territories have legalized cannabis for medical and / or recreational adult use. Such state and territorial laws are in conflict with the federal CSA, which makes cannabis use and possession illegal at the federal level. Because cannabis is a Schedule I controlled substance, however, the development of a legal cannabis industry under the laws of these states is in conflict with the CSA, which makes cannabis use and possession illegal on a national level. The United States Supreme Court has confirmed that the federal government has the right to regulate and criminalize cannabis, including for medical purposes, and that federal law criminalizing the use of cannabis preempts state laws that legalize its use. We would likely be unable to execute our business plan if the federal government were to strictly enforce federal law regarding cannabis.

In light of such conflict between federal laws and state laws regarding cannabis, the administration under President Obama had effectively stated that it was not an efficient use of resources to direct law federal law enforcement agencies to prosecute those lawfully abiding by state-designated laws allowing the use and distribution of medical cannabis. For example, the DOJ Deputy Attorney General of the Obama administration, James M. Cole, issued a memorandum (the “Cole Memo”) to all United States Attorneys providing updated guidance to federal prosecutors concerning cannabis enforcement under the CSA (see “Business—Government and Industry Regulation—The Cole Memo”). In addition, the Financial Crimes Enforcement Network (“FinCEN”) provided guidelines on February 14, 2014, regarding how financial institutions can provide services to cannabis-related businesses consistent with their Bank Secrecy Act obligations (see “Business—Government and Industry Regulation—FinCEN”).

Congress previously enacted an omnibus spending bill that included a provision (the “Rohrabacher-Blumenauer Amendment”) prohibiting the DOJ from using funds to prevent states with medical cannabis laws from implementing such laws. This provision is renewed annually by Congress, and is current through September 30, 2021. In August 2016, a Ninth Circuit federal appeals court ruled in United States v. McIntosh that the Rohrabacher-Blumenauer Amendment bars the DOJ from spending funds on the prosecution of conduct that is allowed by state medical cannabis laws, provided that such conduct is in strict compliance with applicable state law. In March 2015, bipartisan legislation titled the Compassionate Access, Research Expansion, and Respect States Act (the “CARERS Act”) was introduced, proposing to allow states to regulate the medical use of cannabis by changing applicable federal law, including by reclassifying cannabis under the Controlled Substances Act to a Schedule II controlled substance and thereby changing the plant from a federally-criminalized substance to one that has recognized medical uses. More recently, the Respect State Marijuana Laws Act of 2017 has been introduced in the U.S. House of Representatives, which proposes to exclude persons who produce, possess, distribute, dispense, administer or deliver marijuana in compliance with state laws from the regulatory controls and administrative, civil and criminal penalties of the CSA.

These developments previously were met with a certain amount of optimism in the cannabis industry, but (i) neither the CARERS Act nor the Respect State Marijuana Laws Act of 2017 have yet been adopted, (ii) the Rohrabacher-Blumenauer Amendment, being an amendment to an appropriations bill that must be renewed annually, has not currently been renewed beyond September 30, 2021, and (iii) the ruling in United States v. McIntosh is only applicable precedent in the Ninth Circuit, which does not include Colorado, the state where we currently primarily operate.

Furthermore, on January 4, 2018, former U.S. Attorney General, Jeff Sessions, issued a memorandum for all U.S. Attorneys (the “Sessions Memo”) stating that the Cole Memo was rescinded effectively immediately. In particular, Mr. Sessions stated that “prosecutors should follow the well-established principles that govern all federal prosecutions,” which require “federal prosecutors deciding which cases to prosecute to weigh all relevant considerations, including federal law enforcement priorities set by the Attorney General, the seriousness of the crime, the deterrent effect of criminal prosecution, and the cumulative impact of particular crimes on the community.” The Sessions Memo went on to

13

state that given the DOJ’s well-established general principles, “previous nationwide guidance specific to marijuana is unnecessary and is rescinded, effective immediately.”

In response to the Sessions Memo, U.S. Attorney Bob Troy for the District of Colorado, the state in which our principal business operations are presently located, issued a statement on January 4, 2018, stating that the United States Attorney’s Office in Colorado is already guided by the well-established principles referenced in the Sessions Memo, “focusing in particular on identifying and prosecuting those who create the greatest safety threats to our communities around the state. We will, consistent with the Attorney General’s latest guidance, continue to take this approach in all of our work with our law enforcement partners throughout Colorado.”

It is unclear at this time whether the Sessions Memo will be rescinded by the Biden administration; nor is it clear whether the Biden administration will strongly enforce the federal laws applicable to cannabis or what types of activities will be targeted for enforcement. However, a significant change in the federal government’s enforcement policy with respect to current federal laws applicable to cannabis could cause significant financial damage to us. We may be irreparably harmed by a change in enforcement policies of the federal government depending on the nature of such change.  As of the date of this Report, we have provided products and services to state-approved cannabis cultivators and dispensary facilities. As a result, strict enforcement of federal prohibitions regarding cannabis could subject the Company to criminal prosecution.

Additionally, financial transactions involving proceeds generated by cannabis-related conduct can form the basis for prosecution under the federal money laundering statutes, unlicensed money transmitter statutes and the Bank Secrecy Act. Prior to the DOJ's rescission of the “Cole Memo”, supplemental guidance from the DOJ issued under the Obama administration directed federal prosecutors to consider the federal enforcement priorities enumerated in the “Cole Memo” when determining whether to charge institutions or individuals with any of the financial crimes described above based upon cannabis-related activity. It is unclear what impact the recent rescission of the “Cole Memo” will have, but federal prosecutors may increase enforcement activities against institutions or individuals that are conducting financial transactions related to cannabis activities.

Additionally, as we are always assessing potential strategic acquisitions of new businesses, we may in the future also pursue opportunities that include growing and/or distributing medical or recreational cannabis, should we determine that such activities are in the best interest of the Company and our stockholders. Any such pursuit would involve additional risks with respect to the regulation of cannabis, particularly if the federal government determines to strictly enforce all federal laws applicable to cannabis.

Federal prosecutors have significant discretion and no assurance can be given that the federal prosecutor in each judicial district where we operate our business will not choose to strictly enforce the federal laws governing cannabis production or distribution. Any change in the federal government's enforcement posture with respect to state-licensed cultivation of medical-use cannabis, including the enforcement postures of individual federal prosecutors in judicial districts where we purchase properties, would result in our inability to execute our business plan, and we would likely suffer significant losses, which would adversely affect the trading price of our securities. Furthermore, following any such change in the federal government's enforcement position, we could be subject to criminal prosecution, which could lead to imprisonment and/or the imposition of penalties, fines, or forfeiture.

The potential regulation of cannabis by the US Food and Drug Administration could subject us to additional costs and regulatory requirements

Should the federal government legalize cannabis, it is possible that the US Food and Drug Administration (FDA), would seek to regulate it under the Food, Drug and Cosmetics Act of 1938. Additionally, the FDA may issue rules and regulations including good manufacturing practices, related to the growth, cultivation, harvesting and processing of medical cannabis. Clinical trials may be needed to verify efficacy and safety. It is also possible that the FDA would require that facilities where medical-use cannabis is grown register with the FDA and comply with certain federally prescribed regulations. In the event that some or all of these regulations are imposed, the impact they would have on the cannabis industry is unknown, including what costs, requirements and possible prohibitions may be enforced. If we are

14

unable to comply with the regulations or registration as prescribed by the FDA it may have an adverse effect on our business, operating results and financial condition.

Any potential growth in the cannabis industry continues to be subject to new and changing state and local laws and regulations.

Continued development of the cannabis industry is dependent upon continued legislative legalization of cannabis at the state level, and a number of factors could slow or halt progress in this area, even where there is public support for legislative action. Any delay or halt in the passing or implementation of legislation legalizing cannabis use, or its cultivation, sale and distribution, or the re-criminalization or restriction of cannabis at the state level could negatively impact our business. Additionally, changes in applicable state and local laws or regulations, including zoning restrictions, permitting requirements, and fees, could restrict the products and services we offer or impose additional compliance costs on us or our customers and tenants. Violations of applicable laws, or allegations of such violations, could disrupt our business and result in a material adverse effect on our operations. We cannot predict the nature of any future laws, regulations, interpretations or applications, and it is possible that regulations may be enacted in the future that will be materially adverse to our business.

Our business, results of operations and financial condition may be adversely affected by pandemic infectious diseases, particularly the recent novel coronavirus strain known as COVID-19.

Pandemic infectious diseases, such as the current COVID-19 strain, may adversely impact our business, consolidated results of operations and financial condition. The global spread of COVID-19 has created significant volatility and uncertainty and economic disruption. The extent to which COVID-19 impacts our business, operations and financial results will depend on numerous evolving factors that we may not be able to accurately predict, including: the duration and scope of the pandemic; governmental, business and individuals’ actions that have been and continue to be taken in response to the pandemic; the impact of the pandemic on economic activity and actions taken in response; the effect on our customers and customer demand our services, products and solutions; our ability to sell and provide its services and solutions, including as a result of travel restrictions and people working from home; the ability of our customers to pay for our services and solutions; and any closures of our offices and the offices and facilities of our customers.  COVID-19, as well as measures taken by governmental authorities to limit the spread of this virus, may interfere with the ability of our employees, suppliers, and other business providers to carry out their assigned tasks or supply materials or services at ordinary levels of performance relative to the requirements of our business, which may cause us to materially curtail certain of our business operations.  We require additional funding and such funding may not be available to us as a result of contracting capital markets resulting from the COVID-19 pandemic. Any of these events could materially adversely affect our business, financial condition, results of operations and/or stock price.

The cannabis industry faces significant opposition, and any negative trends will adversely affect our business operations.

We are substantially dependent on the continued market acceptance, and the proliferation of consumers, of medical and recreational cannabis. We believe that with further legalization, cannabis will become more accepted, resulting in growth in consumer demand. However, we cannot predict the future growth rate or future market potential, and any negative outlook on the cannabis industry may adversely affect our business operations.

The recreational cannabis industry is highly dependent upon consumer perception regarding the safety, efficacy and quality of the recreational cannabis produced. Cannabis is a controversial topic, and consumer perception of our products may be significantly influenced by scientific research or findings, regulatory investigations, litigation, media attention and other publicity regarding the consumption of recreational cannabis products. There can be no assurance that future scientific research, findings, regulatory proceedings, litigation, media attention or other research findings or publicity will be favorable to the recreational cannabis market or any particular product, or consistent with earlier publicity. Future research reports, findings, regulatory proceedings, litigation, media attention or other publicity that are perceived as less favorable than, or that question, earlier research reports, findings or publicity could have a material adverse effect on the demand for our products and our business, results of operations, financial condition and cash flows. Dependence upon consumer perceptions means that adverse scientific research reports, findings, regulatory proceedings, litigation, media

15

attention or other publicity, whether or not accurate or with merit, could have a material adverse effect on our business and results of operations. Further, adverse publicity reports or other media attention regarding the safety, efficacy and quality of recreational cannabis in general, or our products specifically, or associating the consumption of recreational cannabis with illness or other negative effects or events, could have such a material adverse effect. Such adverse publicity reports or other media attention could arise even if the adverse effects associated with such products resulted from consumers’ failure to consume such products appropriately or as directed.

Large, well-funded business sectors may have strong economic reasons to oppose the development of the cannabis industry. For example, medical cannabis may adversely impact the existing market for the current “cannabis pill” sold by mainstream pharmaceutical companies. Should cannabis displace other drugs or products, the medical cannabis industry could face a material threat from the pharmaceutical industry, which is well-funded and possesses a strong and experienced lobby. Any inroads the pharmaceutical, or any other potentially displaced, industry or sector could make in halting or impeding the cannabis industry could have a detrimental impact on our business.

We operate an agricultural business and are subject to weather and climate conditions.

Our business involves the growing of recreational cannabis, an agricultural product. Such business will be subject to the risks inherent in the agricultural business, such as insects, plant diseases and similar agricultural risks. Further, to the extent that our products are grown outside, we are subject to weather and climate conditions. Extended cold streaks, rain or snow, or generally cold weather or climate, could materially adversely affect our cannabis plants. Accordingly, there can be no assurance that natural elements will not have a material adverse effect on any future production of our products.

We operate in a highly competitive industry.

The markets for ancillary businesses in the medical marijuana and recreational marijuana industries are competitive and evolving. There is no material aspect of our business that is protected by patents, copyrights, trademarks, or trade names, and we face strong competition from larger companies that may offer similar products and services to ours. Many of our current and potential competitors have longer operating histories, significantly greater financial, marketing and other resources and larger client bases than us, and there can be no assurance that we will be able to successfully compete against these or other competitors.

Given the rapid changes affecting the global, national, and regional economies generally and the medical marijuana and recreational marijuana industries, in particular, we may not be able to create and maintain a competitive advantage in the marketplace. Our success will depend on our ability to keep pace with any changes in our markets, particularly, legal and regulatory changes. Our success will also depend on our ability to respond to, among other things, changes in the economy, market conditions, and competitive pressures. Any failure by us to anticipate or respond adequately to such changes could have a material adverse effect on our financial condition and results of operations.

Unfavorable tax treatment of cannabis businesses

Under Section 280E of the United States Internal Revenue Code of 1986 as amended (“Section 280E”), “no deduction or credit shall be allowed for any amount paid or incurred during the taxable year in carrying on any trade or business if such trade or business (or the activities which comprise such trade or business) consists of trafficking in controlled substances (within the meaning of schedule I and II of the Controlled Substances Act) which is prohibited by Federal law or the law of any state in which such trade or business is conducted.” This provision has been applied by the U.S. Internal Revenue Service to cannabis operations, prohibiting them from deducting expenses directly associated with the sale of cannabis. Although the IRS issued a clarification allowing the deduction of certain expenses that can be categorized as cost of sales, the scope of such items is interpreted very narrowly and include the cost of seeds, plants, and labor related to cultivation, while the bulk of operating costs and general administrative costs are not permitted to be deducted. Section 280E therefore has a significant impact on the retail side of cannabis, but a lesser impact on cultivation, processing, production and packaging operations. A result of Section 280E is that an otherwise profitable business may, in fact, operate at a loss, after taking into account its U.S. income tax expenses.

16

We may be limited in our ability to utilize, or may not be able to utilize, net operating loss carryforwards to reduce our future tax liability.

 

We have federal and state net operating loss carryforwards that may be limited or expire unused.  The Company is currently evaluating whether there have been one or more ownership changes pursuant to IRC 382 and 383.  If we determine there were one or more ownership changes under these rules, the use of our U.S. federal and state net operating loss carryforwards may be limited and/or otherwise expired unused.  Any such limitation or expiration could materially affect our ability to offset future tax liabilities with net operating losses.

We may be unable to obtain capital to execute our business plan.

In order to execute on our business plan, we will need additional capital. However, there can be no assurance that we will be able to obtain financing on agreeable terms, if at all, and any future sale of our equity securities will dilute the ownership of our existing stockholders and could be at prices substantially below the price of the shares of common stock sold in the past. If we are unable to obtain the necessary capital, we may need to delay the implementation of or curtail our business plan.

We face risks associated with strategic acquisitions and our business strategy.

As an important part of our roll-up business strategy, we strategically acquire businesses and real property, some of which may be material. These acquisitions involve a number of financial, accounting, managerial, operational, legal, compliance and other risks and challenges, including the following, any of which could adversely affect our results of operations:

The applicable restrictions on the cannabis industry and its participants limit the number of available suitable businesses and real properties that we can acquire;
Any acquired business or real property could under-perform relative to our expectations and the price that we paid for it, or not perform in accordance with our anticipated timetable;
We may incur or assume significant debt in connection with our acquisitions;
Acquisitions could cause our results of operations to differ from our own or the investment community’s expectations in any given period, or over the long term; and
Acquisitions could create demands on our management that we may be unable to effectively address, or for which we may incur additional costs.

Additionally, following any business acquisition, we could experience difficulty in integrating personnel, operations, financial and other systems, and in retaining key employees and customers.

We may record goodwill and other intangible assets on our consolidated balance sheet in connection with our acquisitions. If we are not able to realize the value of these assets, we may be required to incur charges relating to the impairment of these assets, which could materially impact our results of operations.

Our ability to grow our business depends on state laws pertaining to the cannabis industry.

Continued development of the cannabis industry depends upon continued legislative authorization of cannabis at the state level. The status quo of, or progress in, the cannabis industry is not assured and any number of factors could slow or halt further progress in this area. While there may be ample public support for legislative action permitting the manufacture and use of cannabis, numerous factors impact the legislative process. For example, many states that voted to legalize medical and/or adult-use cannabis have seen significant delays in the drafting and implementation of industry regulations and issuance of licenses. In addition, burdensome regulation at the state level could slow or stop further development of the medical-use cannabis industry, such as limiting the medical conditions for which medical cannabis can be recommended by physicians for treatment, restricting the form in which medical cannabis can be consumed, imposing significant registration requirements on physicians and patients or imposing significant taxes on the growth, processing and/or retail sales of cannabis, which could have the impact of dampening growth of the cannabis industry and making it difficult for cannabis businesses, including our tenants, to operate profitably in those states. Any one of

17

these factors could slow or halt additional legislative authorization of cannabis, which could harm our results of operations, business and prospects.

Applicable state laws may prevent us from maximizing our potential income.

Depending on the laws of each particular state, we may not be able to fully realize our potential to generate profit. For example, some states have residency requirements for those directly involved in the cannabis industry, which may impede our ability to contract with cannabis businesses in those states. Furthermore, cities and counties are being given broad discretion to ban certain cannabis activities. Even if these activities are legal under state law, specific cities and counties may ban them.

Assets used in conjunction with cannabis businesses may be forfeited to the federal government.

Any assets used in conjunction with the violation of federal law are potentially subject to federal forfeiture, even in states where cannabis is legal. In July 2017, the U.S. Department of Justice issued a new policy directive regarding asset forfeiture, referred to as the "equitable sharing program." Under this new policy directive, federal authorities may adopt state and local forfeiture cases and prosecute them at the federal level, allowing for state and local agencies to keep up to 80% of any forfeiture revenue. This policy directive represents a reversal of the U.S. Department of Justice's policy under the Obama administration, and allows for forfeitures to proceed that are not in accord with the limitations imposed by state-specific forfeiture laws. This new policy directive may lead to increased use of asset forfeitures by local, state and federal enforcement agencies. If the federal government decides to initiate forfeiture proceedings against cannabis businesses, our investment in those businesses may be lost.

Our operating locations could be targets for theft and our physical security measures may not prevent all security breaches

Our operating locations could be targets for theft. While we have implemented security measures at our operating locations and we continue to monitor and improve security measures, our cultivation and processing facilities could be subject to break-ins, robberies and other breaches in security. If there is a breach in security and we fall victim to a robbery or theft, the loss of cannabis plants, cannabis oils, cannabis flowers and cultivation and processing equipment could have a material adverse impact on our business, financial condition and results of operations.

To the extent that our business involves the movement and transfer of cash which is collected from locations and deposited into financial institutions, there is a risk of theft or robbery during the transport of cash. We may engage a security firm to provide security in the transport and movement of large amounts of cash. While we have taken steps to prevent theft or robbery of cash during transport, there can be no assurance that there will not be a security breach during the transport and the movement of cash involving the theft of product or cash.

Our future success depends on our ability to grow and expand our customer base and operational territory.

Our success and the planned growth and expansion of our business depend on our products and services achieving greater and broader acceptance, resulting in a larger customer base, and on the expansion of our operations into new markets. However, there can be no assurance that customers will purchase our products and/or services, or that we will be able to continually expand our customer base. Additionally, if we are unable to effectively market or expand our product and/or service offerings, we will be unable to grow and expand our business or implement our business strategy.

Operating in new markets may expose us to new operational, regulatory or legal risks and subject us to increased compliance costs. We may need to modify our existing business model and cost structure to comply with local regulatory or other requirements. Facilities we open in new markets may take longer to reach expected revenue and profit levels on a consistent basis, may have higher construction, occupancy or operating costs, and may present different competitive conditions, consumer preferences and spending patterns than we anticipate. Any of the above could materially impair our ability to increase sales and revenue.

18

We and our existing and potential customers, clients and tenants have difficulty accessing the service of banks, which may make it difficult for them to operate.

Financial transactions involving proceeds generated by cannabis-related conduct can form the basis for prosecution under the federal money laundering statutes, unlicensed money transmitter statute and the Bank Secrecy Act. Previous guidance issued by the FinCen, a division of the U.S. Department of the Treasury, clarifies how financial institutions can provide services to cannabis-related businesses consistent with their obligations under the Bank Secrecy Act. Prior to the DOJ’s announcement in January 2018 of the rescission of the “Cole Memo” and related memoranda, supplemental guidance from the DOJ directed federal prosecutors to consider the federal enforcement priorities enumerated in the “Cole Memo” when determining whether to charge institutions or individuals with any of the financial crimes described above based upon cannabis-related activity. It is unclear what impact the recent rescission of the “Cole Memo” will have, but federal prosecutors may increase enforcement activities against institutions or individuals that are conducting financial transactions related to cannabis activities. The increased uncertainty surrounding financial transactions related to cannabis activities may also result in financial institutions discontinuing services to the cannabis industry.

Because the use, sale and distribution of cannabis remains illegal under federal law, many banks will not accept deposits from or provide other bank services to businesses involved with cannabis. Consequently, those businesses involved in the cannabis industry continue to encounter difficulty establishing banking relationships, which may increase over time. Our inability to maintain our current bank accounts would make it difficult for us to operate our business, increase our operating costs, and pose additional operational, logistical and security challenges and could result in our inability to implement our business plan. Furthermore, the inability to open bank accounts may make it difficult for our existing and potential customers, clients and tenants to operate and may make it difficult for them to contract with us.

Conditions in the economy, the markets we serve and the financial markets generally may adversely affect our business and results of operations.

Our business is sensitive to general economic conditions. We believe that the state of global economic conditions is particularly uncertain due to recent and expected shifts in political, legislative and regulatory conditions concerning, among other matters, international trade and taxation, and the impact of recent or future natural disasters and/or health and safety epidemics, including the outbreak of the COVID-19 virus in the first quarter of 2020. An uneven recovery or a renewed global downturn may put pressure on our sales due to reductions in customer demand as well as customers deferring purchases. Slower economic growth, volatility in the credit markets, high levels of unemployment, and other challenges that affect the economy adversely could affect us and our customers and suppliers. If growth in the economy or in any of the markets we serve slows for a significant period, if there is a significant deterioration in the economy or such markets or if improvements in the economy do not benefit the markets we serve, our business and results of operations could be adversely affected.

We depend on our management, certain key personnel and board of directors, as well as our ability to attract, retain and motivate qualified personnel.

Our future success depends largely upon the experience, skill, and contacts of our key personnel, officers and directors, and the loss of the services of these key personnel, officers or directors, particularly our chief executive officer and chairman of our board of directors, may have a material adverse effect upon our business. Additionally, our revenues are largely driven by several employees with particular expertise in cannabis-related security, apparel and operations. If one of these key employees were to leave, it would negatively impact our short and long-term results from operations. Shortages in qualified personnel could also limit our ability to successfully implement our growth plan. As we grow, we will need to attract and retain highly skilled experts in the cannabis industry, as well as managerial, sales and marketing, security and finance personnel. There can be no assurance, however, that we will be able to attract and retain such personnel.

19

Our reputation and ability to do business may be negatively impacted by the improper conduct by our business partners, employees or agents.

We depend on third party suppliers to produce and timely ship our orders. Products purchased from our suppliers are resold to our customers. These suppliers could fail to produce products to our specifications or quality standards and may not deliver units on a timely basis. Any changes in our suppliers to resolve production issues could disrupt our ability to fulfill orders. Any changes in our suppliers to resolve production issues could also disrupt our business due to delays in finding new suppliers.

Furthermore, we cannot provide assurance that our internal controls and compliance systems will always protect us from acts committed by our employees, agents or business partners in violation of U.S. federal or state laws. Any improper acts or allegations could damage our reputation and subject us to civil or criminal investigations and related shareholder lawsuits, could lead to substantial civil and criminal monetary and non-monetary penalties, and could cause us to incur significant legal and investigatory fees.

Due to our involvement in the cannabis industry, we may have difficulty obtaining various insurance policies that are desired to operate our business, which may expose us to additional risks and financial liabilities.

Insurance that is otherwise readily available, such as workers’ compensation, general liability, and directors’ and officers’ insurance, is more difficult for us to find and more expensive, because of our involvement in the cannabis industry. There are no guarantees that we will be able to find such insurance in the future, or that the cost will be affordable to us. If we are forced to go without such insurance, it may prevent us from entering into certain business sectors, may inhibit our growth, and may expose us to additional risk and financial liabilities. Moreover, insurance against risks such as environmental pollution or other hazards encountered in our operations is not generally available on acceptable terms. We might also become subject to liability for pollution or other hazards which may not be insured against or which we may elect not to insure against because of premium costs or other reasons. Losses from these events may cause us to incur significant costs that could have a material adverse effect upon its financial performance and results of operations.

We may be subject to product liability claims

We face an inherent risk of exposure to product liability claims, regulatory action and litigation if its products are alleged to have caused significant loss or injury. In addition, the sale of our products would involve the risk of injury to consumers due to tampering by unauthorized third parties or product contamination. Previously unknown adverse reactions resulting from human consumption of marijuana alone or in combination with other medications or substances could occur. We may be subject to various product liability claims, including, among others, that our products caused injury or illness or death, include inadequate instructions for use or include inadequate warnings concerning possible side effects or interactions with other substances. A product liability claim or regulatory action against us could result in increased costs, could adversely affect our reputation with its clients and consumers generally, and could have a material adverse effect on our business, results of operations and financial condition. There can be no assurances that we will be able to obtain or maintain product liability insurance on acceptable terms or with adequate coverage against potential liabilities. Such insurance is expensive and may not be available in the future on acceptable terms, or at all. The inability to obtain sufficient insurance coverage on reasonable terms or to otherwise protect against potential product liability claims could prevent or inhibit the commercialization of our current or potential products.

A cybersecurity incident and other technology disruptions could result in a violation of law or negatively impact our reputation and relationships, our business operations and our financial condition.

Information and security risks have generally increased in recent years due to the rise in new technologies and the increased sophistication and activities of perpetrators of cyber-attacks. We use computers in substantially all aspects of our business operations and we also use mobile devices and other online activities to connect with our employees, customers, tenants, suppliers and other parties. Such uses give rise to cybersecurity risks, including the risk of security breaches, espionage, system disruption, theft and inadvertent release of information. Our business involves the storage and transmission of numerous classes of sensitive and/or confidential information and intellectual property, including

20

employees’, customers’, tenants’ and suppliers’ personally identifiable information and financial and strategic information about us.

If we fail to adequately assess and identify cybersecurity risks associated with our business operations, we may become increasingly vulnerable to such risks. Even the most well protected information, networks, systems and facilities remain potentially vulnerable because the techniques used in such attempted security breaches evolve and generally are not recognized until launched against a target, and in some cases are designed not to be detected and, in fact, may not be detected. Accordingly, we, our customers and our suppliers may be unable to anticipate these techniques or to implement adequate security barriers or other preventative measures, and thus it is impossible for us, our customers and our suppliers to entirely mitigate this risk. Further, in the future we may be required to expend additional resources to continue to enhance information security measures and/or to investigate and remediate any information security vulnerabilities. We can provide no assurances that the measures we have implemented to prevent security breaches and cyber incidents will be effective in the event of a cyber-attack.

The theft, destruction, loss, misappropriation or release of sensitive and/or confidential information or intellectual property, or interference with our information technology systems or the technology systems of third-parties on which we rely, could result in business disruption, negative publicity, violation of privacy laws, loss of tenants, loss of customers, potential liability and competitive disadvantage, any of which could result in a material adverse effect on financial condition or results of operations.

We may be required to recognize impairment charges that could materially affect our results of operations.

We assess our intangible assets, and our other long-lived assets as and when required by GAAP to determine whether they are impaired. If they are impaired, we would record appropriate impairment charges. It is possible that we may be required to record significant impairment charges in the future and, if we do so, our results of operations could be materially adversely affected.

Changes in accounting standards could affect our reported financial results.

Our management uses significant judgment, estimates and assumptions in applying GAAP. New accounting standards that may be applicable to our financial statements, or changes in the interpretation of existing standards, could have a significant effect on our reported results of operations for the affected periods.

Risks Related to the Securities Markets and Ownership of Our Common Stock

The price of our common stock is volatile, and the value of your investment could decline.

The market price of our common stock has been, and may in the future, be volatile. Between January 1, 2015, and December 31, 2020, the closing price of our stock has ranged from a low of $0.27 per share to a high of $10.35 per share. Accordingly, it is difficult to forecast the future performance of our common stock. The market price of our common stock may be higher or lower than the price you pay, depending on many factors, some of which are beyond our control and may not be related to our operating performance. These fluctuations could cause you to lose all or part of your investment in our common stock. Factors that could cause fluctuations in the trading price of our common stock include the following:

regulatory developments at the federal, state or local level;
announcements of new products, services, relationships with strategic partners, acquisitions or other events by us or our competitors;
changes in general economic conditions;
price and volume fluctuations in the overall stock market from time to time;
significant volatility in the market price and trading volume of similar companies in our industry;
fluctuations in the trading volume of our shares or the size of our public float;

21

actual or anticipated changes in our operating results or fluctuations in our operating results;
major catastrophic events;
sales of large blocks of our stock; or
changes in senior management or key personnel.

 

In addition, if the market for cannabis company stocks or the stock market in general experiences loss of investor confidence, the trading price of our common stock could decline for reasons unrelated to our business, operating results or financial condition. The trading price of our common stock might decline in reaction to events that affect other companies in our industry, even if these events do not directly affect us. In the past, following periods of volatility in the market price of a company’s securities, securities class action litigation has often been brought against that company. If our stock price continues to be volatile, we may become the target of securities litigation, which could result in substantial costs and divert our management’s attention and resources from our business. This could have a material adverse effect on our business, operating results and financial condition.

Trading and listing of securities of cannabis related businesses, including our common stock, may be subject to restrictions.

In the United States, many clearing houses for major broker-dealer firms, including Pershing LLC, the largest clearing, custody and settlement firm in the United States, have refused to handle securities or settle transactions of companies engaged in cannabis related business. This means that certain broker-dealers cannot accept for deposit or settle transactions in the securities of cannabis related businesses.  Further, stock exchanges in the United States, including Nasdaq and the New York Stock Exchange, have historically refused to list certain cannabis related businesses, including cannabis retailers, that operate primarily in the United States.  Our existing operations, and any future operations or investments, may become the subject of heightened scrutiny by clearing houses and stock exchanges, in addition to regulators and other authorities in the United States.  Any existing or future restrictions imposed by Pershing LLC, or any other applicable clearing house, stock exchange or other authority, on trading in our common stock could have a material adverse effect on the liquidity of our common stock.

We do not intend to pay dividends for the foreseeable future.

We do not currently anticipate paying dividends in the foreseeable future. The payment of dividends on our common stock will depend on our earnings and financial condition, as well as on other business and economic factors affecting our business, as our board of directors may consider relevant. Our current intention in the foreseeable future is to apply net earnings, if any, to increasing our capital base and our development and marketing efforts. There can be no assurance that we will ever have sufficient earnings to declare and pay dividends to the holders of our common stock and, in any event, a decision to declare and pay dividends is at the sole discretion of our board of directors. As a result, you may only receive a return on your investment in our common stock if the market price of our common stock increases compared to the price at which you purchased our common stock, which may never occur.

Were our common stock to be considered penny stock, and therefore become subject to the penny stock rules, U.S. broker-dealers may be discouraged from effecting transactions in shares of our common stock.

Broker-dealers are generally prohibited from effecting transactions in “penny stocks” unless they comply with the requirements of Section 15(h) of the Securities Exchange Act of 1934 (the “Exchange Act”) and the rules promulgated thereunder. These rules apply to the stock of companies whose shares are not traded on a national stock exchange, trade at less than $5.00 per share or who do not meet certain other financial requirements specified by the Securities and Exchange Commission (the “SEC”). Trades in our common stock are subject to these rules, which include Rule 15g-9 under the Exchange Act, which imposes certain requirements on broker/dealers who sell securities subject to the rule to persons other than established customers and accredited investors. For transactions covered by the rule, brokers/dealers must make a special written determination that the penny stock is a suitable investment for purchasers of the securities and receive the purchaser’s written agreement to the transaction prior to sale.

The penny stock rules also require a broker/dealer, prior to effecting a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document prepared by the SEC that provides information about

22

penny stocks and the nature and level of risks in the penny stock market. A broker/dealer also must provide the customer with current bid and offer quotations for the relevant penny stock and information on the compensation of the broker/dealer and its salesperson in the transaction. A broker/dealer must also provide monthly account statements showing the market value of each penny stock held in a customer’s account. The bid and offer quotations, and the broker/dealer and salesperson compensation information, must be given to the customer orally or in writing prior to effecting the transaction and must be given to the customer in writing before or with the customer’s confirmation.

Our securities have in the past constituted “penny stock” within the meaning of the rules. Were our common stock to again be considered penny stock, and therefore become subject to the penny stock rules, the additional sales practice and disclosure requirements imposed upon U.S. broker-dealers may discourage such broker-dealers from effecting transactions in shares of our common stock, which could severely limit the market liquidity of such shares and impede their sale in the secondary market.

Our stockholders may experience significant dilution.

We have a significant number of warrants and options to purchase our common stock outstanding, the exercise of which would be dilutive to stockholders. In certain instances, the exercise prices are subject to adjustment if we issue or sell shares of our common stock or equity-based instruments at a price per share less than the exercise price then in effect. In such case, both the issuance and the adjustment would be dilutive to stockholders.

We may from time to time finance our future operations or acquisitions through the issuance of equity securities, which securities may also have rights and preferences senior to the rights and preferences of our common stock. We may also grant options to purchase shares of our common stock to our directors, employees and consultants, the exercise of which would also result in dilution to our stockholders.

We may face continuing challenges in complying with the Sarbanes-Oxley Act, and any failure to comply or any adverse result from management’s evaluation of our internal control over financial reporting may have an adverse effect on our stock price.

As a smaller reporting company as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, we are required to evaluate our internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act of 2002 (“Section 404”). Section 404 requires us to include an internal control report with our Annual Report on Form 10-K. The report must include management’s assessment of the effectiveness of our internal control over financial reporting as of the end of the fiscal year. This report must also include disclosure of any material weaknesses in internal control over financial reporting that we have identified.

Failure to comply, or any adverse results from such evaluation, could result in a loss of investor confidence in our financial reports and have an adverse effect on the trading price of our equity securities. Achieving continued compliance with Section 404 may require us to incur significant costs and expend significant time and management resources. We cannot assure you that we will be able to fully comply with Section 404 or that we will be able to conclude that our internal control over financial reporting is effective at fiscal year-end. As a result, investors could lose confidence in our reported financial information, which could have an adverse effect on the trading price of our securities, as well as subject us to civil or criminal investigations and penalties. In addition, our independent registered public accounting firm may not agree with our management’s assessment or conclude that our internal control over financial reporting is operating effectively.

We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices.

As a public company we have incurred, and particularly after we are no longer a smaller reporting company, we will continue to incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the OTCQB Market and other applicable securities rules and regulations impose various requirements on public

23

companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs, particularly as we hire additional financial and accounting employees to meet public company internal control and financial reporting requirements, and will make some activities more time-consuming and costly.

We are evaluating these rules and regulations, and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.

Pursuant to Section 404, we will be required to furnish a report by our management on our internal control over financial reporting. However, while we remain a smaller reporting company with less than $100 million in revenue, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, including through hiring additional financial and accounting personnel, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section 404. If we identify one or more material weaknesses in our internal control over financial reporting, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.

ITEM 1B. UNRESOLVED STAFF COMMENTS.

None.

ITEM 2. PROPERTIES

The Company’s corporate headquarters are located in Denver, Colorado and our Cultivation facility is located in Boulder Colorado. Both locations are leased by the Company. For additional information regarding the lease terms and provisions, see Note 10. “Leases” in our consolidated financial statements included in Item 8. “Financial Statements and Supplementary Data.”

ITEM 3. LEGAL PROCEEDINGS

From time to time, we may be involved in various claims and legal actions in the ordinary course of business. We are not currently involved in any material legal proceedings outside the ordinary course of our business.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

24

PART II

ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Market Information

General Cannabis Corp common stock (CANN) is listed for trading on the OTC Market’s OTCQB.

Holders

As of March 29, 2021, we had approximately 69 holders of record of our common stock. A substantially greater number of holders of the Company’s common stock are “street name” or beneficial holders, whose shares of record are held by banks, brokers and other financial institutions. In addition, our Articles of Incorporation authorize the Board to issue up to 5,000,000 shares of preferred stock. The provisions in the Articles of Incorporation relating to the preferred stock allow directors to issue preferred stock with multiple votes per share and dividend rights, which would have priority over any dividends paid with respect to the holders of common stock. The issuance of preferred stock with these rights may make the removal of management difficult even if the removal would be considered beneficial to stockholders, generally, and will have the effect of limiting stockholder participation in certain transactions such as mergers or tender offers if these transactions are not favored by management.

Dividend Policy

Holders of our common stock are entitled to receive dividends as may be declared by the Board. The Board is not restricted from paying any dividends, but is not obligated to declare a dividend. No cash dividends have ever been declared and it is not anticipated that cash dividends will be paid in the near future. We currently intend to retain any future earnings to finance future growth. Any future determination to pay dividends will be at the discretion of the Board and will depend on our financial condition, results of operations, capital requirements and other factors the Board considers relevant.

ITEM 6. SELECTED FINANCIAL DATA

As a "smaller reporting company" as defined by Item 10 of Regulation S-K, we are not required to provide the information required by this Item.

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Management’s discussion and analysis (“MD&A”) should be read in conjunction with the consolidated financial statements and accompanying notes included in Item 8 of this Annual Report on Form 10-K (annual report), which include additional information about our accounting policies, practices and the transactions underlying our financial results. The preparation of our consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP) requires us to make estimates and assumptions that affect the reported amounts in our consolidated financial statements and the accompanying notes, including various claims and contingencies related to lawsuits, taxes, environmental and other matters arising during the normal course of business. We apply our best judgment, our knowledge of existing facts and circumstances and actions that we may undertake in the future in determining the estimates that affect our consolidated financial statements. We evaluate our estimates on an ongoing basis using our historical experience, as well as other factors we believe appropriate under the circumstances, such as current economic conditions, and adjust or revise our estimates as circumstances change. As future events and their effects cannot be determined with precision, actual results may differ from these estimates. Our MD&A contains forward-looking statements that discuss, among other things, future expectations and projections regarding future developments, operations and financial condition. All forward-looking statements are based on management’s existing beliefs about present and future events outside of management’s control and on assumptions that may prove to be

25

incorrect. If any underlying assumptions prove incorrect, our actual results may vary materially from those anticipated, estimated, projected or intended. We undertake no obligation to publicly update or revise any forward-looking statements to reflect actual results, changes in expectations or events or circumstances after the date of this Report is filed. General Cannabis Corp and its subsidiaries are referred to collectively as “GCC” “the Company,” “we, “us” or “our” in the following discussion and analysis.

Results of Operations

The following tables set forth, for the periods indicated, statements of operations data. The tables and the discussion below should be read in conjunction with the accompanying consolidated financial statements and the notes thereto appearing in Item 8 in this Report.

Consolidated Results

Year ended December 31, 

Percent

 

2020

2019

Change

Change

 

Revenues

    

$

7,120,040

    

$

3,666,346

    

$

3,453,694

    

94

%

Costs and expenses

 

(13,185,819)

 

(12,528,035)

 

(657,784)

5

%

Other expense

 

(1,553,043)

 

(4,946,569)

 

3,393,526

(69)

%

Net loss from continuing operations

 

(7,618,822)

 

(13,808,258)

 

6,189,436

(45)

%

Loss from discontinued operations

 

(60,870)

 

(1,675,539)

 

1,614,669

(96)

%

Net loss

$

(7,679,692)

$

(15,483,797)

$

7,804,105

(50)

%

The following discussion of our results of operations relates to our continuing operations. See Note 3 to the consolidated financial statements for information concerning discontinued operations.

Revenues

Our acquisition of SevenFive Farm in May 2020 added approximately $2.3 million in revenues for the year ended December 31, 2020. Our Operations Segment increased revenues by $1.6 million to $5.2 million for the year ended December 31, 2020, from $3.6 million for the year ended December 31, 2019, primarily driven by an increase in product sales. See Segment discussions below for further details.

Costs and expenses

Year ended December 31, 

Percent

 

    

2020

    

2019

    

Change

    

Change

 

Cost of revenues

$

5,467,197

$

2,467,100

$

3,000,097

122

%

Selling, general and administrative

 

3,699,079

 

4,379,800

 

(680,721)

 

(16)

%

Stock-based compensation

 

1,504,389

 

3,966,621

 

(2,462,232)

 

(62)

%

Professional fees

 

2,299,693

 

1,598,818

 

700,875

 

44

%

Depreciation and amortization

 

215,461

 

115,696

 

99,765

 

86

%

$

13,185,819

$

12,528,035

$

657,784

 

5

%

The increase in cost of revenues is primarily driven by our acquisition of SevenFive Farm in May 2020 and an increase of cost of sales in our Operations Segment directly correlated to the increase in product sales in the year ended December 31, 2020. See Segment discussions below for further details.

Selling, general and administrative expense decreased by $0.7 million to $3.7 million for the year ended December 31, 2020 from $4.4 million for the year ended December 31, 2019 primarily due to management’s emphasis on cost controls and decreases in salary expense due to the discontinuation of certain business operations; decreased marketing costs; and decreased travel expenses due to COVID-19 pandemic.

26

Stock-based compensation included the following:

Year ended December 31, 

Percent

 

2020

2019

Change

Change

 

Employee awards

    

$

1,411,442

    

$

3,880,938

    

$

(2,469,496)

    

(64)

%

Consulting awards

 

92,947

 

85,683

 

7,264

 

8

%

$

1,504,389

$

3,966,621

$

(2,462,232)

 

(62)

%

Employee awards are issued under our 2014 Equity Incentive Plan, which was approved by shareholders on June 26, 2015, and expense varies primarily due to the number of stock options granted and the share price on the date of grant. The decrease in expense for the year ended December 31, 2020 is due to the restructuring of the Company in the first quarter of 2020 and the reduction in workforce. We decreased our employee count by over 50% resulting in a sharp decrease in employee award expense. Consulting awards are granted to third parties in lieu of cash for services provided.

Professional fees consist primarily of accounting and legal expenses and have increased from 2019 due to increased activity related to acquisitions and fund raising activities.

Depreciation and amortization expense increased in 2020 due to the acquisition of SevenFive Farm.

Other Expense

Year ended December 31, 

Percent

 

2020

2019

Change

Change

 

Amortization of debt discount

    

$

295,256

    

$

2,019,726

    

$

(1,724,470)

    

(85)

%

Interest expense

 

453,522

 

345,371

 

108,151

 

31

%

Loss on extinguishment of debt

 

1,638,009

 

377,300

 

1,260,709

 

334

%

(Gain) loss on derivative liability

 

(735,796)

 

2,204,172

 

(2,939,968)

 

(133)

%

Gain on sale of building

 

(139,187)

 

 

(139,187)

 

(100)

%

Loss on investment

41,239

41,239

100

%

$

1,553,043

$

4,946,569

$

(3,393,526)

 

(69)

%

Amortization of debt discount was lower in 2020 compared to 2019, due to the April 2018 debt paid off in the second quarter of 2019. This was offset slightly by new debt issued in the third and fourth quarters of 2019 and the first quarter of 2020. Interest expense increased in 2020 due to the new debt entered in the third and fourth quarters of 2019 and the first quarter of 2020. The increase in the loss on extinguishment of debt in 2020 is primarily due to the conversion and extension of the SBI debt, the exchange of the 12% Notes into the 15% Notes, and the extension of a portion of the 15% Notes. The (gain)/loss on warrant derivative liability reflects the change in the fair value of the 2019 Warrants. The gain on the sale of the building is from the sale of our building in March 2020.

Operations Consulting and Products

Year ended December 31, 

Percent

 

2020

2019

Change

Change

 

Revenues

    

$

5,195,000

    

$

3,570,909

    

$

1,624,091

    

45

%

Costs and expenses

 

(5,312,427)

 

(3,372,174)

 

(1,940,253)

 

58

%

Segment operating (loss) income

$

(117,427)

$

198,735

$

(316,162)

 

(159)

%

The increase in revenues primarily related to an increase in product sales throughout 2020 with COVID-related decreases in services and application fees completed in 2020. The increase in expenses is directly related to the increase in product sales.

27

Cultivation

Year ended December 31, 

Percent

 

2020

2019

Change

Change

 

Revenues

    

$

2,279,867

    

$

    

$

2,279,867

    

100

%

Costs and expenses

 

(1,865,399)

 

 

(1,865,399)

 

100

%

Segment operating income

$

414,468

$

$

414,468

 

100

%

This is a new segment in 2020, therefore all amounts are an increase from the prior year.

Investments

Year ended December 31, 

Percent

 

2020

2019

Change

Change

 

Revenues

    

$

103,837

    

$

95,437

    

$

8,400

    

9

%

Costs and expenses

 

(125,000)

 

(71,723)

 

(53,277)

 

74

%

Segment operating (loss) income

$

(21,163)

$

23,714

$

(44,877)

 

(189)

%

The increase in revenue in 2020 is due to a note that went into default during the second quarter of 2020, triggering a higher interest rate in 2020. All revenue is interest, and loan origination fees related to these new notes. The increase in costs and expenses in 2020 is due to an allowance on our notes receivables due to the notes going into default. In January 2021, we collected all the interest receivable on one of the notes in default.

Non-GAAP Financial Measures

Adjusted EBITDA is a non-GAAP financial measure. We define Adjusted EBITDA as net income (loss) attributable to common stockholders calculated in accordance with GAAP, adjusted for the impact of stock-based compensation expense, acquisition related expenses, non-recurring professional fees in relation to litigation and other non-recurring expenses, depreciation and amortization, amortization of debt discounts and equity issuance costs, loss on extinguishment of debt, interest expense, income taxes and certain other non-cash items. Below we have provided a reconciliation of Adjusted EBITDA per share to the most directly comparable GAAP measure, which is net income (loss) per share.

We believe that the disclosure of Adjusted EBITDA provides investors with a better comparison of our period-to-period operating results. We exclude the effects of certain items when we evaluate key measures of our performance internally and in assessing the impact of known trends and uncertainties on our business. We also believe that excluding the effects of these items provides a more comparable view of the underlying dynamics of our operations. We believe such information provides additional meaningful methods of evaluating certain aspects of our operating performance from period to period on a basis that may not be otherwise apparent on a GAAP basis. This supplemental financial information should be considered in addition to, not in lieu of, our consolidated financial statements.

28

Year ended December 31, 

2020

2019

Net loss attributable to common stockholders

    

$

(8,510,186)

    

$

(17,824,797)

Adjustment for loss from discontinued operations

 

60,870

 

1,675,539

Loss from continuing operations attributable to common stockholders

 

(8,449,316)

 

(16,149,258)

Adjustments:

 

  

 

  

Deemed dividend

830,494

2,341,000

Stock-based compensation

 

1,504,389

 

3,966,621

Depreciation and amortization

215,461

115,696

Amortization of debt discount and equity issuance costs

 

295,256

 

2,019,726

Loss on extinguishment of debt

 

1,638,009

 

377,300

Interest expense

 

453,522

 

345,371

Gain on sale of building

(139,187)

Loss on investment

41,239

(Gain) loss on derivative liability

 

(735,796)

 

2,204,172

Severance

103,302

114,557

Acquisition related expenses

326,095

318,681

Nonrecurring professional services

1,348,598

562,323

Total adjustments

 

5,881,382

 

12,365,447

Adjusted EBITDA

$

(2,567,934)

$

(3,783,811)

Liquidity

Sources of liquidity

Our sources of liquidity include cash generated from operations, the cash exercise of common stock options and warrants, debt, and the issuance of common stock or other equity-based instruments. We anticipate our more significant uses of resources will include funding operations, developing infrastructure, and business acquisitions.

In December 2020, we received $1,940,000 in cash in a private placement with certain accredited investors pursuant to which we issued and sold 10% senior convertible promissory notes.

In July 2020, we received $815,000 in cash by issuing 2,046,196 shares of our common stock and 1,534,647 warrants to purchase common stock.

In May and June 2020, we received $2,185,000 in cash by issuing 5,485,814 shares of our common stock and 4,114,360 warrants to purchase common stock.

In May 2020, we received $1,421,934 from the sale of our corporate office building.

During January through March of 2020, we received $525,000 in cash in a private placement with certain accredited investors pursuant to the 15% Notes.

29

Sources and uses of cash

We had cash of approximately $750,218 and $122,390, respectively, at December 31, 2020 and 2019. Our cash flows from operating, investing and financing activities were as follows:

Year ended December 31, 

2020

2019

Net cash used in operating activities

    

$

(5,000,388)

    

$

(5,328,661)

Net cash provided by (used in) investing activities

 

1,107,163

 

(753,639)

Net cash provided by (used in) financing activities

 

4,424,000

 

(1,649,875)

Net cash used in operating activities decreased slightly in 2020 due to an increase in revenue as well as the acquisition of SevenFive Farm which provides positive operating cash flows.

Net cash provided by investing activities for the year ended December 31, 2020 consisted of $1,421,934 from the sale of the office building in Denver, CO and purchase of equipment of $314,771.

Net cash provided by financing activities are primarily related to the sale of common stock and warrants and proceeds from notes payable. This is offset by paying off debt.

Capital Resources

We have no material commitments for capital expenditures as of December 31, 2020. Part of our growth strategy, however, is to acquire businesses. We would anticipate funding such activity through cash on hand, the issuance of debt, common stock, warrants for our common stock or a combination thereof.

Off-Balance Sheet Arrangements

We currently have no off-balance sheet arrangements.

Critical Accounting Policies

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the amounts of revenues and expenses. Critical accounting policies are those that require the application of management’s most difficult, subjective or complex judgments, often because of the need to make estimates about the effect of matters that are inherently uncertain and that may change in subsequent periods. In applying these critical accounting policies, our management uses its judgment to determine the appropriate assumptions to be used in making certain estimates. Actual results may differ from these estimates.

We define critical accounting policies as those that are reflective of significant judgments and uncertainties and which may potentially result in materially different results under different assumptions and conditions. In applying these critical accounting policies, our management uses its judgment to determine the appropriate assumptions to be used in making certain estimates. These estimates are subject to an inherent degree of uncertainty.

Business Combinations

Amounts paid for acquisitions are allocated to the assets acquired and liabilities assumed based on their estimated fair value at the date of acquisition. The fair value of identifiable intangible assets is based on detailed valuations that use information and assumptions provided by management, including expected future cash flows. We allocate any excess purchase price over the fair value of the net assets and liabilities acquired to goodwill. Identifiable intangible assets with finite lives are amortized over their useful lives. Acquisition-related costs, including advisory, legal, accounting,

30

valuation and other costs, are expensed in the periods in which the costs are incurred. The results of operations of acquired businesses are included in the consolidated financial statements from the acquisition date.

Goodwill and Intangibles

Goodwill represents the excess of purchase price over the fair value of identifiable net assets acquired in a business combination. Goodwill and long-lived intangible assets are tested for impairment at least annually in accordance with the provisions of ASC No. 350, Intangibles-Goodwill and Other (“ASC No. 350”). ASC No. 350 requires that goodwill be tested for impairment at the reporting unit level (operating segment or on level below an operating segment) on an annual basis and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carry value. Application of the goodwill impairment test requires judgement, including the identification of reporting units, assignment of assets and liabilities to reporting units, assignment of goodwill to reporting units, and determination of the fair value of each reporting unit. We test goodwill annually in April, unless an event occurs that would cause the us to believe the value is impaired at an interim date.

Intangible assets with finite useful lives are amortized over their respective estimated useful lives and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable.

Impairment of Long-lived Assets

We periodically evaluate whether the carrying value of property and equipment has been impaired when circumstances indicate the carrying value of those assets may not be recoverable. The carrying amount is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. If the carrying value is not recoverable, the impairment loss is measured as the excess of the asset’s carrying value over its fair value.

Our impairment analyses require management to apply judgment in estimating future cash flows as well as asset fair values, including forecasting useful lives of the assets, assessing the probability of different outcomes, and selecting the discount rate that reflects the risk inherent in future cash flows. If the carrying value is not recoverable, we assess the fair value of long-lived assets using commonly accepted techniques, and may use more than one method, including, but not limited to, recent third-party comparable sales and undiscounted cash flow models. If actual results are not consistent with our assumptions and estimates, or our assumptions and estimates change due to new information, we may be exposed to an impairment charge in the future.

Accounting for Discontinued Operations

We regularly review underperforming assets to determine if a sale or disposal might be a better way to monetize the assets. When an asset group is considered for sale or disposal, we review the transaction to determine if or when the entity qualifies as a discontinued operation in accordance with the criteria of FASB ASC Topic 205-20, Discontinued Operations. The FASB has issued authoritative guidance that raises the threshold for disposals to qualify as discontinued operations. Under this guidance, a discontinued operation is (1) a component of an entity or group of components that have been disposed of or are classified as held for sale and represent a strategic shift that has or will have a major effect on an entity’s operations and financial results, or (2) an acquired business that is classified as held for sale on the acquisition date.

Debt with Equity-linked Features

We may issue debt that has separate warrants, conversion features, or no equity-linked attributes.

Debt with warrants – When we issue debt with warrants, we treat the warrants as a debt discount, record as a contra-liability against the debt, and amortize the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations. The offset to the contra-liability is recorded as additional paid in capital in our consolidated balance sheets. If the debt is retired early, the associated debt discount is then recognized

31

immediately as amortization of debt discount expense in the consolidated statement of operations. The debt is treated as conventional debt.

We determine the value of the non-complex warrants using the Black-Scholes Option Pricing Model (“Black-Scholes”) using the stock price on the date of issuance, the risk-free interest rate associated with the life of the debt, and the volatility of our stock. For warrants with complex terms, we use the binomial lattice model to estimate their fair value.

Modification of Debt - When we change the terms of existing notes payable, we evaluate the amendments under ASC 470-50, Debt Modification and Extinguishment to determine whether the change should be treated as a modification or as a debt extinguishment. This evaluation includes analyzing whether there are significant and consequential changes to the economic substance of the note. If the change is deemed insignificant then the change is considered a debt modification, whereas if the change is substantial the change is reflected as a debt extinguishment.

Convertible Debt - When we issue debt with a conversion feature, we must first assess whether the conversion feature meets the requirements to be treated as a derivative. If the conversion feature within convertible debt meets the requirements to be treated as a derivative, we estimate the fair value of the convertible debt derivative using Black-Scholes upon the date of issuance, using the stock price on the date of issuance, the risk free interest rate associated with the life of the debt, and the estimated volatility of our stock. If the conversion feature is not treated as a derivative, we assess whether it is a beneficial conversion feature (“BCF”). A BCF exists if the effective conversion price of the convertible debt instrument is less than the stock price on the commitment date. This typically occurs when the effective conversion price is less than the fair value of the stock on the date the instrument was issued. The value of a BCF is equal to the intrinsic value of the feature, the difference between the effective conversion price and the fair value of the common stock into which it is convertible.

Equity-based Payments

We estimate the fair value of equity-based instruments issued to employees or to third parties for services or goods using Black-Scholes or the Binomial Model, which requires us to estimate the volatility of our stock and forfeiture rate.

Revenue Recognition

On January 1, 2018, we adopted ASC Topic 606, “Revenue from Contracts with Customers” (“ASC 606”). The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing U.S. GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation.

The following five steps are applied to achieve that core principle:

Step 1: Identify the contract with the customer;
Step 2: Identify the performance obligations in the contract;
Step 3: Determine the transaction price;
Step 4: Allocate the transaction price to the performance obligations in the contract; and
Step 5: Recognize revenue when the company satisfies a performance obligation.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISKS

As a "smaller reporting company" as defined by Item 10 of Regulation S-K, we are not required to provide information required by this Item.

32

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

33

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Shareholders and Board of Directors of

General Cannabis Corp.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of General Cannabis Corp. (the “Company”) as of December 31, 2020 and 2019, the related consolidated statements of operations, changes in stockholders’ equity and cash flows for each of the two years in the period ended December 31, 2020, and the related notes (collectively referred to as the “financial statements”).  In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2020, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

Incremental Borrowing Rate (Leases)

Description of the Matter

As discussed in Note 10 to the consolidated financial statements, the Company’s reported right-of-use assets, current lease liabilities and long-term lease liabilities, utilize discount rates to calculate the estimated present value of future lease payments for all leases under ASC Topic 842 at the lease commencement date, and the lessee is required to remeasure its lease liability and adjust the related right-of-use asset upon any lease modifications not accounted for as a separate contract. Since the Company’s lease does not provide an implicit rate, management utilized a third-party valuation specialist to assist in estimating the incremental borrowing rates used in its present value calculation, which required subjectivity. The

34

incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.  The Company’s current operating lease had a lease commencement date in May 2020, and a lease modification in December 2020. As of the lease commencement date on May 2020, the incremental borrowing rate used to determine the operating lease liability was 22.8%.  As of the lease modification date in December 2020, the incremental borrowing rate was 20.0%.

Auditing management’s assessment of its incremental borrowing rate is highly subjective and judgmental as the Company has no collateralized outstanding debt nor committed credit facilities, secured or otherwise, that would have comparable collateral or similar terms as their underlying lease. Based on the level of management judgment, we have determined the incremental borrowing rate to be a critical audit matter.  This required a high degree of auditor judgment and an increased extent of effort, including the need to involve our valuation specialists, when performing audit procedures to evaluate the reasonableness of management’s estimation of the incremental borrowing rate.

How we Addressed the Matter in Our Audit

With the assistance of our valuation specialists, our audit procedures included, amongst others:

We obtained an understanding of management’s process in regards to the methodology used and the factors considered around the inputs, sources of data used and assumptions and estimates made in determining the Company’s incremental borrowing rates, including those over management’s review of its third-party specialist valuation report.
We reviewed the contractual terms of the original lease agreement and the modified lease agreement to ensure the commencement date and modification date, any lease term extensions and/or early termination clauses were properly considered in determining the appropriate lease term for calculating the incremental borrowing rates.
We evaluated the reasonableness of the valuation methods and assumptions used by management and the Company’s valuation specialist to estimate the incremental borrowing rates for borrowing amounts and terms comparable to their outstanding leases.
We performed a sensitivity analysis on incremental borrowing rates used to determine the impact rate changes could have on the present value calculation of the Company’s operating lease right-of-use asset and operating lease liability.

Acquisition Date Fair Value of Trade Name Intangible Asset

Description of the Matter

As discussed in Note 2 to the consolidated financial statements, on May 13, 2020, the Company acquired Dalton Adventures, LLC in a business combination. As part of the transaction, the Company acquired fixed assets, inventory, a cultivation license and the trade name of the business, SevenFive Farm. Due to the complexity in determining fair value, management utilized a third-party valuation specialist to assist in calculating the acquisition date fair value of the trade name intangible asset. The acquisition date fair value of $1.0 million, which was determined using the relief from royalty method, was allocated to the acquired trade name intangible asset.

Auditing management’s assessment of the acquisition date fair value of the trade name intangible asset is highly subjective and judgmental.  Based on the level of management judgment, we have determined the evaluation of the acquisition date fair value of the trade name intangible asset to be a critical audit matter. Testing the assumptions regarding future revenue growth rates and discount rate, which were used to determine the fair value, involved a high degree of subjectivity, auditor judgment and an increased extent of effort, including the need to involve our valuation specialist, when performing audit procedures to evaluate the reasonableness of management’s estimation of the acquisition date fair value of the trade name intangible asset.

How we Addressed the Matter in Our Audit

With the assistance of our valuation specialists, our audit procedures included, amongst others:

We obtained an understanding of management’s process with regards to the methodology used, and the factors considered around the inputs, sources of data used, assumptions and estimates used in the relief from royalty method to determine the acquisition date fair value of the trade name intangible asset, including those over management’s review of its third-party specialist valuation report.

35

We tested the mathematical accuracy of the underlying schedules used in the valuation report to ensure the completeness and accuracy of the reports.
We evaluated the Company’s future revenue growth rates by comparing them to historical results to ensure the reasonableness of these forecasts.
We assessed the appropriateness of the overall approach and use of the relief from royalty method as the overall approach to determining the fair value of the trade name.
We evaluated the reasonableness of the methodology and assumptions used by the specialist to determine the discount and royalty rates utilized to value the trade name intangible asset.

/s/ Marcum llp

Marcum llp

We have served as the Company’s auditor since 2019.

Melville, NY

April 1, 2021

36

GENERAL CANNABIS CORP

CONSOLIDATED BALANCE SHEETS

December 31, 

2020

2019

Assets

 

  

 

  

Current assets

 

  

 

  

Cash and cash equivalents

$

750,218

$

122,390

Accounts receivable, net of allowance of $27,000 and $111,000 as of December 31, 2020 and 2019, respectively

 

327,790

 

85,204

Current portion of notes receivable, net of allowance of $125,000 and $0 as of December 31, 2020 and 2019, respectively

350,000

375,000

Inventories, net

371,799

Prepaid expenses and other current assets

 

744,396

 

546,970

Assets of discontinued operations

 

5,551

 

422,671

Total current assets

 

2,549,754

 

1,552,235

Note receivable, net

 

 

93,333

Right-of-use operating lease asset

1,836,455

Property and equipment, net

455,222

1,507,327

Investment, held for sale

 

208,761

 

250,000

Intangible assets, net

984,375

Goodwill

2,484,200

Assets of discontinued operations

99,109

Total assets

$

8,518,767

$

3,502,004

Liabilities and Stockholders' Equity

 

 

  

Current liabilities

 

 

  

Accounts payable and accrued expenses

$

1,513,761

$

1,221,195

Interest payable

 

16,790

 

93,375

Customer deposits

517,931

562,803

Operating lease liability, current

370,800

Accrued stock payable

 

94,861

 

80,657

Current portion of notes payable (net of discount)

2,269,977

Related party note payable (net of discount)

 

 

60,374

Warrant derivative liability

 

561,368

 

4,620,593

Liabilities of discontinued operations

 

54,641

 

357,242

Total current liabilities

 

3,130,152

 

9,266,216

Operating lease liability, non-current

1,499,280

Long-term notes payable

2,598,965

Related party long-term notes payable (net of discount)

289,579

Total liabilities

7,517,976

9,266,216

Commitments and contingencies (Note 15)

Stockholders’ equity (deficit)

 

  

 

  

Preferred stock, no par value; 5,000,000 shares authorized; no shares issued and outstanding as of December 31, 2020 and 2019

Common stock, $0.001 par value; 200,000,000 and 100,000,000 shares authorized; 60,813,673 shares and 39,497,480 shares issued and outstanding on December 31, 2020 and 2019, respectively

60,813

39,498

Additional paid-in capital

 

75,891,414

 

61,468,034

Accumulated deficit

 

(74,951,436)

 

(67,271,744)

Total stockholders’ equity (deficit)

 

1,000,791

 

(5,764,212)

Total liabilities & stockholders’ equity (deficit)

$

8,518,767

$

3,502,004

The accompanying notes are an integral part of these consolidated financial statements.

37

GENERAL CANNABIS CORP

CONSOLIDATED STATEMENTS OF OPERATIONS

Year ended December 31, 

2020

2019

Revenue

Service

$

1,081,291

$

1,787,863

Cultivation sales

2,279,867

Product sales

3,655,045

1,783,046

Interest

103,837

95,437

Total revenue

7,120,040

3,666,346

Costs and expenses

Cost of sales

5,467,197

2,467,100

Selling, general and administrative

3,699,079

4,379,800

Stock-based compensation expense

1,504,389

3,966,621

Professional fees

2,299,693

1,598,818

Depreciation and amortization

215,461

115,696

Total costs and expenses

13,185,819

12,528,035

Operating loss

(6,065,779)

(8,861,689)

Other expenses (income)

Amortization of debt discount and equity issuance costs

295,256

2,019,726

Interest expense

453,522

345,371

Loss on extinguishment of debt

1,638,009

377,300

(Gain) loss on derivative liability

(735,796)

2,204,172

Other income, net

(97,948)

Total other expenses, net

1,553,043

4,946,569

Net loss from continuing operations before income taxes

(7,618,822)

(13,808,258)

Loss from discontinued operations

(60,870)

(1,675,539)

Loss from operations before income taxes

(7,679,692)

(15,483,797)

Provision for income taxes

Net loss

(7,679,692)

(15,483,797)

Deemed dividend

(830,494)

(2,341,000)

Net loss attributable to common stockholders

$

(8,510,186)

$

(17,824,797)

Per share data - Basic and diluted

Net loss from continuing operations per share

$

(0.15)

$

(0.36)

Net loss from discontinued operations per share

$

$

(0.04)

Net loss attributable to common stockholders per share

$

(0.17)

$

(0.47)

Weighted average number of common shares outstanding

50,895,301

38,106,781

The accompanying notes are an integral part of these consolidated financial statements.

38

GENERAL CANNABIS CORP

CONSOLIDATED STATEMENTS OF CASH FLOWS

Year ended December 31, 

2020

2019

Cash flows from operating activities

  

 

  

Net loss

$

(7,679,692)

$

(15,483,797)

Adjustments to reconcile net loss to net cash used in operating activities:

 

  

 

  

Amortization of debt discount and equity issuance costs

 

295,256

 

2,019,726

Depreciation and amortization

 

217,635

 

196,247

Amortization of loan origination fees

(6,667)

(13,333)

Loss on extinguishment of debt

1,638,009

377,300

Non-cash lease expense

286,228

Bad debt expense

134,059

174,249

Impairment of assets

147,035

Loss on disposal of property and equipment

37,193

104,803

(Gain) loss on warrant derivative liability

 

(735,796)

 

2,204,172

Stock-based compensation

 

1,504,389

 

3,966,621

Loss on investment

41,239

Gain on sale of building

(139,187)

Changes in operating assets and liabilities, net of acquisitions

 

 

Accounts receivable

 

36,249

 

(101,766)

Prepaid expenses and other assets

 

(165,252)

 

(138,254)

Inventories

 

(186,538)

 

(23,772)

Accounts payable and accrued liabilities

(24,910)

1,242,108

Operating lease liabilities

(252,603)

Net cash used in operating activities:

 

(5,000,388)

 

(5,328,661)

Cash flows from investing activities

 

  

 

  

Purchase of property and equipment

 

(314,771)

 

(318,639)

Lending on notes receivable

(705,000)

Proceeds on notes receivable

270,000

Proceeds from sale of building

1,421,934

Net cash provided by (used in) investing activities

 

1,107,163

 

(753,639)

Cash flows from financing activities

 

  

 

Proceeds from sale of common stock and warrants

 

3,000,000

 

2,604,355

Proceeds from the exercise of warrants

90,000

Proceeds from exercise of stock options